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FOREWORD 
 
Most Australians want to know how they can 
keep their brain sharp as they get older – what 
things should they do and not do to keep their 
brain healthy. People affected by dementia and 
their families and friends are anxious to know 
how to slow down the cognitive decline that 
defines the illness. 
 
In general, Australians have a low level of 
awareness of the research evidence that shows 
that health and lifestyle strategies can reduce the 
risk of cognitive decline and dementia. Statistics 
reveal that only 51% of Australians believe it is 
possible to reduce their risk and there is a 
widespread lack of knowledge that what’s good 
for the heart is also good for the brain. 
 
The objective of this paper is to provide an 
updated review of the evidence for dementia risk 
reduction strategies. Modifiable risk and 
protective factors are detailed and the current 
evidence presented for each one. Major reviews 
of the scientific literature are discussed and 
controversial findings are addressed. Current and 
future research projects that will address 
remaining questions and pave the way for 
improved advice about what people can do to 
reduce their dementia risk, are also reviewed. 
 
 An increasing body of evidence suggests that a 
range of lifestyle and health factors has the 
potential to reduce the risk of cognitive decline 
and dementia. Higher levels of mental, social and 
physical activity are associated with lower risk of 
developing dementia while cardiovascular risk 
factors such as diabetes, high blood pressure 
and high cholesterol are associated with 
increased risk. 
 
It seems midlife is a critical time to address these 
modifiable risk factors, but it is never too late to 
develop good brain health habits. Evidence is 
emerging that these same beneficial factors can 
influence the rate of cognitive decline in someone 
with dementia and that by keeping the person 
engaged, and effectively managing other medical 
conditions, their quality of life can be improved. 
 
Dementia is not a normal part of ageing. The 
changes it causes in brain function are the result 
of brain disease for which there is unfortunately 
as yet no cure. However, evidence gathered in 
recent years suggests that modifiable risk factors 
do influence disease progression. While the 
search for disease-modifying drug treatments 
continues, we must capitalise on the available 
evidence for health and lifestyle interventions that 
may reduce risk, as this provides us with the best 
hope of delaying or slowing down dementia. 
Studies reviewed in this paper estimate that 
significantly fewer – many thousands in fact – will 
develop dementia if we address modifiable risk 
factors now. Conversely, if we do nothing, 
numbers will increase rapidly from 280,000 in 
2012 to almost one million in 2050. Of course, 
there are no guarantees for any person. Some 
risk factors for dementia, including older age and 
genetics, cannot be modified. 
 
Increased funding for research is essential. In the 
past 10 years, scientific research has resulted in 
new hope for dementia prevention but much 
more is needed. Additional investment in 
research to consider the prevention, early 
intervention and treatment of dementia, is pivotal 
in addressing the looming epidemic. Dementia 
research in Australia is significantly underfunded 
compared with other chronic diseases such as 
cancer, cardiovascular disease and diabetes. 
 
The publication of this paper coincides with the 
launch of Alzheimer’s Australia’s new brain 
health program, Your Brain Matters: A guide to 
healthy hearts and minds, which we hope will 
encourage all Australians to look after their brain, 
body and heart, in order to maintain brain health 
and reduce their risk of dementia. We believe it is 
everyone’s responsibility to do this. Alzheimer’s 
Australia is committed to conveying this message 
throughout Australia and will continue to develop 
resources to help people understand and apply 
the current evidence. 
 
I commend this paper to all people who are 
interested in what can be done now to address 
dementia prevention for the Australian 
community. My thanks to the authors for their 
efforts to provide this overview of the state of the 
evidence and promising future directions. 
 
 
  
Ita Buttrose AO, OBE 
President, Alzheimer’s Australia 
 
September 2012 
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EXECUTIVE SUMMARY 
 
CAN DEMENTIA BE PREVENTED? 
 
Prevention of dementia is the ultimate aim of a 
large, albeit under resourced, international 
research effort. The success of this effort would 
have enormous benefits for millions of people 
and save billions of dollars in health care costs. 
Conversely, the status quo will see the number of 
Australians living with dementia soar in coming 
years. Many more people will experience and 
seek help for mild cognitive impairment. 
 
There are many different forms of dementia, a 
syndrome caused by brain disease and 
characterised by declining cognitive function that 
impairs daily activities. Dementia can affect 
memory, language, attention, judgement, 
planning, behaviour, mood and personality. Mild 
cognitive impairment does not significantly impair 
daily activities, but often represents an earlier 
stage of cognitive decline. 
 
There is no cure for the common forms of 
cognitive decline and dementia, including the 
most common, Alzheimer’s disease. A cure may 
only be achieved by prevention, because the 
diseases that cause dementia begin many years 
before symptoms become apparent and 
gradually damage the brain until it can no longer 
function normally. Intervening early to stop or 
slow disease progression, before cognitive 
impairment emerges, offers the best hope of 
preventing dementia. 
 
Is this achievable?  It requires breakthroughs in 
early detection and intervention. 
 
New diagnostic technologies have been 
developed that can detect the presence of 
abnormal protein accumulations in the brain that 
characterise Alzheimer’s disease. The disease 
can now be detected by brain scans or 
cerebrospinal fluid tests in the preclinical stage, 
before any cognitive changes occur. 
 
Several clinical trials of potential drug therapies 
against Alzheimer’s disease have been 
conducted in recent years. None have been 
successful. Despite promising evidence that 
these drugs can impede the protein 
accumulations that characterise Alzheimer’s 
disease, when tested with people with 
Alzheimer’s, they have failed to provide clinical 
benefits. 
 
Researchers are now asking whether this is in 
part due to intervening too late in the disease 
process. Trials will soon begin to involve people 
who are in the preclinical phase of Alzheimer’s 
disease. This research offers new hope, 
however, a breakthrough is likely many years 
away. Therapies also need to be found for other 
forms of dementia, which often coexist with 
Alzheimer’s contributing to cognitive impairment. 
 
In the meantime, there is much interest in what 
other strategies might help to prevent or slow 
down cognitive decline and dementia. The 
available evidence indeed supports potential 
benefits of healthy, active lifestyles. These 
cannot definitely prevent dementia, but until 
curative therapies are found, preventative health 
approaches offer hope of reducing risk and 
delaying onset of dementia. 
 
HEALTH AND LIFESTYLE STRATEGIES FOR 
PREVENTION 
 
Higher levels of mental activity throughout life are 
consistently associated with better cognitive 
function and reduced risk of cognitive decline and 
dementia. Almost one in five cases of cognitive 
impairment or dementia may be attributable to 
low levels of mental activity, more than any other 
risk factor, including the major genetic risk factor 
for Alzheimer’s disease. Complex mental activity 
across the lifespan may contribute to brain 
reserve, allowing normal cognitive function to 
continue for longer in the face of underlying 
disease. It may also reduce the protein 
accumulations seen in Alzheimer’s disease. 
 
Higher engagement in social activity is 
associated with reduced risk of cognitive decline 
and dementia. Social engagement has been 
found to have benefits for other health factors 
related to cognitive functioning, such as vascular 
conditions and depression. Social activity is 
cognitively stimulating and may contribute to 
building brain reserve that protects against 
cognitive decline and dementia. 
 
Moderate alcohol consumption is associated with 
better cognitive function and reduced risk of 
dementia. However, excessive amounts over 
time may increase the risk. The benefits of 
moderate alcohol consumption include reducing 
inflammation, increasing HDL (“good”) 
cholesterol, increasing brain blood flow, and 
antioxidant properties, all of which have positive 
effects on brain health. In contrast to the potential 
benefits of moderate alcohol consumption, heavy 
use can lead to brain damage. 
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What we eat is also likely to be important for 
cognitive health, but the evidence is not yet 
conclusive. Dietary choices affect risk for 
cardiovascular disease, high blood pressure, 
diabetes, high cholesterol and obesity, all of 
which in turn are associated with increased risk 
of cognitive impairment and dementia. Dietary 
patterns characterised by higher intake of fruits, 
vegetables, fish, nuts and legumes, and lower 
intake of meats, high fat dairy and sweets seem 
to be associated with lower risk of cognitive 
impairment and dementia. 
 
Regular physical exercise is associated with 
better brain function and reduced risk of cognitive 
decline and dementia. Even simple exercise like 
walking has been shown to be beneficial. 
Physical activity increases brain blood flow, 
stimulates the growth of new neurons and 
synapses, is associated with larger brain volume, 
and reduces the risk of cardiovascular conditions 
associated with increased risk and severity of 
cognitive decline and dementia. 
 
There is a U-shaped relationship between midlife 
body weight and the risk of developing dementia 
later in life, with increased risk found for those 
who are underweight as well as those who are 
obese. Obesity is also associated with increased 
risk for high blood pressure, diabetes, 
cardiovascular disease and cerebrovascular 
disease, which affect brain health and increase 
the risk of dementia. 
 
Smoking has been demonstrated to be a risk 
factor for dementia and cognitive decline. Former 
smokers do not appear to be at increased risk 
compared to never-smokers, suggesting quitting 
smoking may be beneficial for reducing dementia 
risk. Smoking may affect dementia risk via its 
negative effects on the cardiovascular system, 
increased oxidative stress, atherosclerosis and 
inflammation. 
 
Untreated hypertension (high blood pressure) 
increases risk for vascular disease, stroke, and 
related cognitive impairment. Hypertension in 
midlife may also be associated with an increased 
risk of Alzheimer’s disease, however, 
hypertension in old age is not. Hypertension may 
contribute to both vascular damage in the brain 
and Alzheimer’s disease pathology, both of which 
in turn contribute to cognitive impairment. 
Treatment of midlife hypertension has been 
found to reduce dementia risk. 
 
Untreated high total cholesterol at midlife is 
associated with an increased risk of developing 
dementia, especially Alzheimer’s disease. 
Cholesterol levels may decline in the preclinical 
stages of Alzheimer’s disease, so late-life high 
cholesterol is not associated with increased risk. 
Treatment of high cholesterol with statins has 
been associated with reduced risk of dementia in 
several studies. High midlife cholesterol levels 
may accelerate the protein accumulations of 
Alzheimer’s disease and contribute to vascular 
disease, especially atherosclerosis, both of which 
can contribute to cognitive impairment. 
 
Type 2 diabetes and pre-diabetes syndromes 
such as insulin resistance appear to be risk 
factors for cognitive impairment and dementia. 
Few studies have examined the effect of 
treatment of diabetes on dementia risk and the 
results are mixed. Prevention of diabetes, 
through early screening for glucose tolerance and 
insulin resistance and lifestyle modifications for 
those at risk, could reduce the incidence of mild 
cognitive impairment and dementia. Insulin 
resistance and diabetes may accelerate the 
protein accumulations of Alzheimer’s disease and 
contribute to cerebrovascular disease. 
 
YOUR BRAIN MATTERS: A GUIDE TO 
HEALTHY HEARTS AND MINDS 
 
Of the factors that evidence indicates are 
associated with brain health and dementia risk, 
the ten health and lifestyle factors highlighted 
here are the most amenable to modification. 
They form the basis of Your Brain Matters, a new 
program from Alzheimer’s Australia designed to 
raise awareness that cognitive decline is not an 
inevitable part of ageing, that everyone can do 
something to reduce their risk, and that 
preventative strategies are critical at midlife. 
 
The evidence base for this program indicates that 
a life-course approach to dementia prevention 
will reap the most benefit. Many of the 
associations with late life dementia risk are 
strongest when the risk factor is measured at 
midlife. Brain pathology that causes dementia 
likely develops gradually from midlife and 
evidence is emerging that modifiable factors 
influence this pathology. Taken together, there is 
compelling evidence to suggest lifestyle and 
medical interventions in midlife can slow down 
the progression of brain disease and resultant 
cognitive decline. 
 
Some experts cautiously suggest there is not yet 
enough evidence to make firm recommendations, 
but there is consensus that long standing 
preventative approaches that are good for the 
heart will also be good for the brain, and that 
raising awareness of this is important. 
 
Alzheimer’s Australia’s vision is for a society 
committed to the prevention of dementia, while 
valuing and supporting people living with 
dementia. An active, healthy lifestyle and 
effective treatment of cardiovascular risk factors 
may also benefit people diagnosed with 
dementia, helping to slow cognitive decline. 
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Your Brain Matters: A guide to healthy hearts and 
minds provides Australians with three key 
messages that encourage a holistic approach to 
looking after your brain, body and heart at all 
ages: 
 
 
 Keeping your brain active matters 
 Being fit and healthy matters 
 Looking after your heart matters 
 
 
 
The table below summarises Your Brain Matters. For more information, visit yourbrainmatters.org.au. 
 
Health or lifestyle 
factor 
Risk for cognitive decline and dementia 
BRAIN  
Mental activity Higher mental stimulation through education, occupation or leisure is associated 
with lower risk. 
Social activity Higher social interaction in late life is associated with lower risk. 
BODY  
Diet * Findings for individual nutrients are inconsistent. Higher intakes of fruits and 
vegetables and fish seem to be associated with lower risk. 
Physical activity Regular physical exercise at all ages is associated with lower risk. 
HEART  
Blood pressure Untreated midlife high blood pressure is associated with increased risk. 
Cholesterol Untreated midlife high cholesterol is associated with increased risk. 
Diabetes Type 2 diabetes is associated with increased risk. 
Smoking Current smoking is associated with increased risk, former smoking is not. 
Weight Midlife obesity and underweight are associated with increased risk. 
 
* Moderate alcohol consumption is associated with lower risk, but comes with a warning – alcohol 
consumption can cause other health problems. 
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1. INTRODUCTION 
 
In September 2012, Alzheimer's Australia 
launches its new brain health and dementia risk 
reduction program, Your Brain Matters: A guide 
to healthy hearts and minds. This community 
program aims to educate Australians about the 
lifestyle and health factors that could help them 
maintain brain health into old age and reduce 
their risk of dementia. There is compelling 
evidence that a healthy, mentally stimulating and 
physically active lifestyle and prevention or 
control of cardiovascular risk factors are 
associated with better cognitive function and 
lower dementia risk. Nonetheless, it is important 
that there is increased investment in dementia 
research to further build the evidence base. This 
paper outlines current evidence and research 
directions. 
 
 
1.1 COGNITIVE IMPAIRMENT AND DEMENTIA 
 
Dementia is an umbrella term, used to describe a 
syndrome that can have many different causes. 
The syndrome is characterised by gradual 
decline in cognitive abilities and neuropsychiatric 
symptoms. The causes are most commonly brain 
disease including Alzheimer’s disease, Lewy 
body disease, cerebrovascular disease and 
frontotemporal lobar degeneration. These 
diseases begin to damage the brain many years 
before symptoms become apparent and cause a 
progressive decline in functioning as more of the 
brain is damaged. In new diagnostic criteria to be 
published in 2013, the term dementia will be 
replaced by ‘major neurocognitive disorder’ to 
reflect the severity of cognitive impairment at this 
stage of disease [1]. 
 
Because conditions such as Alzheimer’s disease 
have a gradual onset, many affected people 
begin to experience cognitive problems that are 
not severe enough to significantly interfere with 
daily functioning, and so do not meet criteria for 
dementia. This is currently termed mild cognitive 
impairment (MCI) or cognitive impairment – no 
dementia (CIND). In the new diagnostic criteria to 
be published in 2013, these terms will be 
replaced by ‘minor neurocognitive disorder’ [1]. 
Criteria specifically for Alzheimer’s disease label 
this stage as prodromal Alzheimer’s disease [2]. 
 
There is also an initial stage of disease in which 
cognitive function remains normal. In this earliest 
stage, pathology begins to build up in the brain, 
but is not yet sufficient to cause any changes in 
brain function. New neuroimaging techniques and 
measures of proteins in cerebrospinal fluid allow 
this preclinical phase to be detected for 
Alzheimer’s disease. It is this preclinical stage 
that future therapies may target, to stop the 
disease before it affects cognitive function. Even 
therapies that could slow down the progression of 
the pathology and its effects on function would be 
enormously beneficial. 
 
Such therapies do not yet exist and drug 
discovery research and clinical trials are 
continuing. In the meantime, there is much 
community interest in what other strategies might 
help people to avoid or at least slow down 
cognitive decline and dementia, and much 
research is happening in this area. The available 
evidence supports the potential of healthy active 
lifestyles to reduce the risk of cognitive decline 
and dementia. 
 
 
1.2 WHY IS RISK REDUCTION IMPORTANT? 
 
It is estimated that almost 280,000 Australians 
currently live with dementia. Without a significant 
medical breakthrough, that is expected to soar to 
almost 1 million by 2050 [3]. There are many 
more older people with some degree of cognitive 
impairment impacting on their lives [4]. Cognitive 
impairment and dementia already place 
significant burden on the health system and 
economy and this impact is set to rapidly 
increase as the population ages. 
 
While dementia remains incurable, preventative 
health approaches offer some hope of reducing 
this impact. Reducing dementia risk factors has 
the potential to reduce risk and delay onset of 
dementia for individuals, and reduce the 
incidence of dementia in the population. Barnes 
and Yaffe recently estimated that up to half of 
Alzheimer’s disease cases are potentially 
attributable to seven risk factors (diabetes, midlife 
hypertension, midlife obesity, depression, 
physical inactivity, smoking and cognitive 
inactivity) [5]. They further estimated that 3 
million cases of Alzheimer’s disease could be 
prevented worldwide by reducing by 25% the 
incidence of these risk factors. Another study 
estimated that a one year delay in the average 
age of onset of Alzheimer’s disease through 
preventive strategies would result in nearly 12 
million fewer cases worldwide by 2050 [6]. 
 
It is also estimated significant impacts can be 
achieved by modifying the risk factor profile in the 
Australian population. For example, a decline in 
the physical inactivity rate by 5% every 5 years 
would reduce dementia prevalence by 11% in 
2051 [7]. That equates to around 100,000 fewer 
Australians living with dementia, as a 
consequence of addressing just one risk factor. 
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Addressing health and lifestyle risk factors in 
those already living with cognitive decline or 
dementia may also be beneficial. Treatment of 
hypertension, high cholesterol, diabetes and 
depression, and maintaining cognitive, physical 
and social activities may help slow cognitive 
decline, or at least ensure cognitive impairment is 
not exacerbated [8]. 
 
While research into therapies that can stop the 
diseases that cause dementia continues, we can 
do something now to inform Australians about the 
potential benefits of risk reduction strategies. 
 
 
1.3 DEMENTIA RISK REDUCTION 
AWARENESS 
 
Despite a growing body of research evidence for 
lifestyle and health strategies that may reduce 
dementia risk, Australians have a low level of 
awareness of these strategies. A review of 
community surveys found that only 51% of 
Australians believed risk reduction is possible, 
while 20% believed nothing can be done to 
reduce dementia risk and the remainder were 
unsure [1]. When asked how risk could be 
reduced, or when presented with factors and 
asked which would reduce risk, mental activity 
was nominated by more people than any other 
strategy, followed by a healthy diet and physical 
exercise. However, the majority of people did not 
agree that reducing cardiovascular risk factors 
(smoking, high blood pressure and high 
cholesterol) could reduce dementia risk. 
 
Survey findings also revealed that few people are 
currently taking steps to reduce their dementia 
risk and many lack motivation to do so [9]. 
 
Evaluation of Alzheimer’s Australia’s Mind your 
Mind program (the predecessor to Your Brain 
Matters) revealed that providing information 
about dementia risk factors and risk reduction 
strategies, via community presentations or a 
website, was able to significantly increase 
people’s knowledge and their motivation to 
improve their brain health related behaviours 
[10,11]. 
 
 
1.4 YOUR BRAIN MATTERS 
 
Your Brain Matters: A guide to healthy hearts and 
minds is an Alzheimer’s Australia program that 
provides Australians with three key messages 
about the modifiable risk and protective factors 
for cognitive decline and dementia. 
 
 Keeping your brain active matters 
 Being fit and healthy matters 
 Looking after your heart matters 
 
The program aims to educate people that there is 
more to maintaining cognitive function than doing 
crossword puzzles, that in fact a holistic 
approach looking after their brain, body and heart 
will give them the best chance of cognitive health 
into old age. It also aims to raise awareness that 
what is good for the heart is good for the brain. 
The ‘Brain’ component of the program includes 
advice that those who are more mentally and 
socially active have better cognitive function and 
lower dementia risk. The ‘Body’ component 
provides advice that healthy choices related to 
alcohol consumption, diet and exercise are 
associated with better cognitive function and 
lower dementia risk. And the ‘Heart’ component 
encourages abstinence from smoking, 
maintaining a healthy weight, regular health 
checks and good control of diabetes, high blood 
pressure and high cholesterol to reduce the risk 
of vascular contributions to dementia. For more 
information about the program, visit 
yourbrainmatters.org.au.  
 
The evidence for the association of each of these 
modifiable lifestyle and health factors with brain 
health and dementia risk is summarised in this 
paper. 
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2. NON-MODIFIABLE RISK FACTORS FOR 
DEMENTIA 
 
2.1 AGE 
 
Older age is the most important risk factor for 
cognitive decline and dementia. The prevalence 
of dementia increases exponentially with age. 1 
in 30 Australians aged 70 to 74 are estimated to 
have dementia, increasing to 1 in 8 of those aged 
80 to 84 and 1 in 3 of those aged 90 to 94 [3]. 
 
Age is a risk factor that cannot be modified and 
has been referred to as ‘the elephant in the room’ 
[12]. Because the modifiable risk factors for 
dementia overlap with those of heart disease and 
other chronic illnesses, perhaps the assumed 
prevention of dementia through addressing 
lifestyle risk factors would be attenuated by 
increased survival of the population to older ages 
[12]. However, if addressing modifiable risk 
factors reduced the number of people developing 
dementia at all ages, there would be less people 
living with the illness even though they lived 
longer. 
 
Despite the important impact of age on the risk of 
developing dementia, research clearly indicates 
there are factors that protect older people from 
developing the illness. Older people with better 
vascular health, who have been more physically, 
mentally and socially active, who don’t smoke 
and who drink alcohol in moderation are 
significantly less likely on average to develop 
dementia. 
 
The modifiable lifestyle and medical risk factors 
for dementia are often conceptualised as 
delaying factors that postpone the onset of 
dementia [13,14]. A brain healthy lifestyle can 
build brain reserve, so that cognitive function 
remains intact for longer in the face of age-
related changes or brain disease. 
 
 
 
 
 
2.2 GENETICS 
 
The genetics of dementia is not fully understood, 
but genes are another non-modifiable risk factor. 
Only a small proportion of dementia cases are 
thought to be directly inherited and caused by 
identified individual gene mutations. The majority 
of dementia cases are sporadic and likely to 
result from a combination of genetic and 
environmental influences. 
 
In the rare familial form of Alzheimer’s disease, 
mutations in the amyloid precursor protein, the 
presenilin 1 and the presenilin 2 genes cause 
autosomal dominant transmission of the disease 
[15]. These genes account for perhaps 1% of 
Alzheimer’s cases. The onset of symptoms in 
familial Alzheimer’s is typically before age 60. 
 
In non-familial or sporadic Alzheimer’s, the 
apolipoprotein E (APOE) gene has been 
identified as a major risk factor [14]. The APOE 
ε4 allele increases risk while the ε2 allele 
appears to be protective. APOE ε4 may also 
increase the risk of cognitive impairment, 
vascular dementia and Lewy body disease. 
 
Familial frontotemporal dementia accounts for 
around 10-15% of all cases [16]. The majority of 
cases are sporadic. Of the familial forms, the 
MAPT (microtubule associated protein tau) and 
progranulin genes account for around 50% of 
cases. Mutations of the C9ORF72 gene have 
recently been implicated as a fairly common 
cause of frontotemporal dementia [17]. There 
also rare genetic forms of Lewy body disease, 
cerebrovascular disease and other causes of 
dementia. 
 
Genes obviously play an important role in the 
development of cognitive decline and dementia. 
However, only in a few cases can the cause be 
attributed solely to a genetic mutation. More 
research is needed to clarify the interactions 
between age, genes and environmental risk 
factors for dementia. 
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3. MODIFIABLE FACTORS – BRAIN  
 
3.1 MENTAL ACTIVITY 
 
Higher participation in mentally stimulating 
activities is associated with better cognitive 
function and reduced risk of cognitive 
decline and dementia. Those with a history of 
higher education, mentally demanding 
occupations or participation in mentally 
challenging leisure activities are consistently 
found to have a lower risk of developing 
dementia. 
 
3.1.1 Mental activity and dementia risk 
 
Reduced risk of cognitive decline and dementia 
appear to be associated with: 
 Higher levels of education 
 Mentally demanding occupations 
 More cognitively stimulating leisure activities 
 Higher intelligence 
 
Meta-analyses suggest reduced risk of dementia 
for those with high educational attainment 
compared to low, those with high occupational 
status compared to low, and those participating 
in more cognitively stimulating leisure activities 
compared to those participating in few such 
activities [18,19]. A dose-response relationship 
is also evident, such that dementia risk 
increases with decreasing levels of education for 
instance [19]. 
 
Importantly for older or retired people, increased 
complex mental activity in late life is associated 
with lower dementia risk independent of other 
predictors such as education [18].  
 
A recent French study found 18% of cases of 
mild cognitive impairment or dementia could be 
attributed to low crystallised intelligence [20], 
and a review found 19% of cases of Alzheimer’s 
disease could be attributed to low education [5]. 
In both cases, these markers of lower levels of 
mental activity during life accounted for more 
cases of cognitive impairment or dementia than 
any other risk factor, including the major genetic 
risk factor for Alzheimer’s disease. 
 
Brain training games and computer programs 
have not as yet been shown to reduce the risk of 
dementia [21]. 
 
3.1.2 Mental activity and the brain 
 
It is hypothesised that complex mental activity 
across the lifespan may reduce the risk or delay 
the onset of dementia by improving brain reserve 
[18,19]. Mental activity, challenge and learning 
stimulate the growth of new neurons and 
synapses [19]. High levels of complex mental 
activity across the lifespan were found to be 
correlated with a reduced rate of hippocampal 
atrophy [22]. Complex cognitive activity 
contributes to neurological brain reserve 
(increased synapses, neural numbers and brain 
volume) and behavioural brain reserve (flexible 
cognitive strategies). This reserve may allow 
normal cognitive function to continue for longer in 
the face of underlying degeneration such as in 
Alzheimer’s disease [19,23]. 
 
Recent findings that greater participation in 
cognitively stimulating activities in early and 
midlife is associated with reduced beta amyloid in 
the brain at late-life, as measured by positron 
emission tomography (PET) scans, suggest that 
higher levels of mental activity may also prevent 
or slow the onset and progression of Alzheimer’s 
disease [24]. Neural activity appears to regulate 
the secretion of beta amyloid, and individuals who 
participate in a variety of cognitively stimulating 
activities during the lifespan may develop more 
efficient neural processing that result in less beta 
amyloid deposition [24]. 
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3.2 SOCIAL ACTIVITY 
 
Being more socially active is associated with 
reduced risk of cognitive decline and 
dementia. This has been shown in several 
studies measuring social engagement in 
different ways. Combining social activity with 
mental and/or physical activity may provide 
even greater benefit in reducing the risk of 
developing dementia. 
 
3.2.1 Social activity and dementia risk 
 
A history of being more socially active is 
associated with reduced cognitive decline and 
risk of developing dementia, for levels of social 
activity measured in a number of different ways 
[14,25]. 
 
The association between social engagement and 
dementia risk has been shown by several 
studies, for example: 
 Participation in high numbers of different 
leisure activities was associated with a 38% 
lower risk of developing dementia in 1,772 
people over age 65 [26]. Activities included 
going to clubs, visiting friends or being 
visited, playing cards and community or 
volunteer work. 
 Larger social networks were associated with 
a 36% lower risk of dementia in 2,249 elderly 
women [27]. 
 Loneliness (perceived isolation) was 
associated with more than double the risk of 
developing dementia in 823 older persons 
[28]. Loneliness was also associated with 
worse cognition at baseline and more rapid 
cognitive decline during follow-up. 
 
 
 
Midlife social activity may also be related to lower 
dementia risk, and increasing social engagement 
in old age appears to be beneficial for cognition 
[25]. 
 
Research suggests that social activities that also 
involve mental stimulation and/or physical activity 
can provide even greater benefit. A study in 
Stockholm investigated mental, physical and 
social components of the leisure activities of 
people aged 75 years and older [29]. All three 
components were associated with a reduced risk 
of dementia after 6 years follow up. Combining 
components offered the greatest benefit, with 
those whose activities included higher levels of 
two or all three components having a 47% 
reduced risk of dementia. 
 
There remains the question of reverse causation 
because most studies in this area commence in 
old age, with participants who may already be 
developing dementia, which may lead to social 
withdrawal [14]. However, overall the evidence 
points in the direction of social engagement being 
protective for cognitive function. 
 
3.2.2 Social activity and the brain 
 
Social activity may benefit brain health and 
cognitive function through a number of 
mechanisms [14]. Social engagement has been 
found to have benefits for other health factors 
that are also related to cognitive functioning, such 
as vascular conditions and depression, and it 
may improve health behaviours such as 
maintaining physical exercise. Social activity may 
also contribute to brain reserve. Interacting with 
other people involves many cognitive functions. 
As with other mentally stimulating activity, this is 
believed to help build up a reserve of healthy 
neurons and synapses that may protect against 
cognitive decline and dementia. 
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4. MODIFIABLE FACTORS – BODY  
 
4.1 ALCOHOL 
 
Consumption of moderate amounts of alcohol 
has been associated with better cognitive 
function and reduced risk of dementia. 
However, excessive amounts over time may 
increase the risk. National guidelines 
recommend consuming no more than 2 
standard drinks a day. 
 
4.1.1 Alcohol and dementia risk 
 
Several studies have found that moderate alcohol 
consumption, compared to abstaining, is 
associated with a lower risk of cognitive decline, 
mild cognitive impairment, any dementia and 
Alzheimer’s disease [30]. There is insufficient 
evidence to promote alcohol consumption to non-
drinkers as a means of reducing dementia risk. 
However, there may be benefits for those 
currently using alcohol moderately. 
 
In a large study of 8,000 people in Rotterdam, 
followed up for an average of 7 years, there was 
a 45% lower risk of dementia in those who 
consumed 1-3 alcoholic drinks per day, 
compared to non-drinkers [31]. 
 
Three meta-analyses found reduced risks of 
around 30 to 40% for those drinking moderate 
levels of alcohol [32-34]. All found significant 
effects for any dementia and Alzheimer’s 
disease. Two also found a significant effect for 
vascular dementia [32,34]. 
 
However, excessive alcohol consumption can 
cause cognitive impairment and may increase the 
risk of dementia [30]. Very heavy drinking over 
time can cause alcohol-related dementia [35]. 
While meta-analyses failed to detect a significant 
association between heavy drinking and 
dementia risk [32,34], several observational 
studies have shown this association. For 
example, in a study of 554 twins in Finland, 
followed for 25 years, binge drinking at least 
monthly in midlife was associated with a more 
than 3-fold increase in the risk of dementia after 
the age of 65 years [36]. 
 
The upper limit of alcohol consumption that is 
safe for maintaining cognitive function has not 
been determined. Alcohol’s potential harmful 
effects for other medical conditions also need to 
be taken into consideration. The National Health 
and Medical Research Council’s Australian 
Guidelines to Reduce Health Risks from Drinking 
Alcohol recommend limiting alcohol intake to no 
more than 2 standard drinks on any day to 
reduce the risk of long term harm [37]. 
 
4.1.2 Alcohol and the brain 
 
The benefits of alcohol may be produced through 
its favourable effects on the cardiovascular 
system, although there may be other 
mechanisms. Moderate alcohol consumption may 
protect against cerebrovascular disease, which 
has been shown to contribute to cognitive 
impairment and clinical dementia. Alcohol 
appears to reduce inflammation, increase HDL 
(‘good’) cholesterol and inhibit blood clotting, all 
of which are thought to protect against vascular 
disease in the body and brain [30,35]. Increasing 
brain blood flow, increasing insulin sensitivity and 
antioxidant properties have also been implicated 
as contributing to alcohol’s protective effect 
[32,33]. 
 
Many alcoholic drinks contain antioxidants, which 
may help reduce oxidative damage in the ageing 
brain. Red wine is particularly rich in the 
antioxidant resveratrol, so many studies of 
alcohol’s effects on dementia risk have focused 
on wine consumption. However, the evidence to 
date does not support any one type of alcoholic 
drink being more protective than any other [30]. 
 
In contrast to the potential benefits of moderate 
alcohol consumption, there is evidence that 
heavy alcohol consumption can have neurotoxic 
effects and lead to brain damage [35]. Many 
chronic alcoholics demonstrate significant brain 
atrophy [35]. 
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4.3 DIET 
 
Diets low in saturated fat and high in fruits 
and vegetables have been associated with 
better brain function and reduced risk of 
dementia. While the benefits of specific 
nutrients are not yet clear, what is good for 
the heart seems to be also good for the brain. 
A healthy diet is likely to contribute to brain 
health and may reduce the risk of developing 
dementia. 
 
4.3.1 Diet, brain health and dementia risk 
 
Many individual nutrients have been studied for 
their potential benefits on cognitive health. More 
recently, dietary patterns most associated with 
reduced risk of dementia have been investigated. 
Dietary choices affect risk for cardiovascular 
disease, high blood pressure, diabetes, high 
cholesterol and obesity, all of which in turn are 
associated with increased risk of cognitive 
impairment and dementia. 
Several prospective studies have found that high 
intakes of saturated and transunsaturated 
(hydrogenated) fats are associated with 
increased risk of dementia, while higher intake of 
polyunsaturated and monounsaturated fats is 
associated with reduced risk of dementia [41]. 
 
The omega 3 fatty acids contained in fish oils are 
thought to reduce inflammation in the brain and 
promote the growth of new neurons. Results are 
conflicting as to whether omega 3 protects 
against dementia [42], but some studies have 
shown an association between higher fish 
consumption and lower dementia risk. 
 
Nutrients with antioxidant properties may help 
protect against oxidative damage, considered 
part of the pathology of Alzheimer’s disease and 
other forms of dementia. Prospective studies 
provide some evidence of lower dementia risk for 
higher intake of specific antioxidants, but results 
are conflicting [43]. A review of studies found no 
effect for vitamin C, and a potential beneficial 
effect for dietary vitamin E but not for vitamin E 
supplements [44]. Clinical trials of antioxidant 
supplements have failed to demonstrate benefits 
in terms of reducing risk of cognitive decline or 
dementia in the elderly, but this doesn’t rule out 
potential benefits of antioxidant strategies begun 
at earlier ages [43,44]. 
Deficiencies of B vitamins (folate, vitamin B6 and 
vitamin B12) and elevated homocysteine levels 
have been associated with increased risk of 
cognitive impairment, Alzheimer’s disease and 
vascular dementia [45]. Homocysteine is an 
amino acid, elevated levels of which are 
associated with increased risk of cardiovascular 
and cerebrovascular disease, and increased 
hippocampal atrophy [46]. 
 
Elevated homocysteine may also increase 
oxidative stress and the production of beta 
amyloid plaques in the brain [46]. Clinical trials in 
older adults have not shown that increasing B 
vitamin intake or using supplements reduces the 
risk of cognitive decline or dementia, however 
some trials demonstrated slowing of brain 
atrophy and improvement in some domains of 
cognitive function [45]. It is possible that if such 
supplements were begun in midlife, when chronic 
elevations in homocysteine could be prevented, 
they would be more beneficial, but further 
research is required to determine this [46]. 
 
Dietary patterns characterised by higher intake of 
fruits, vegetables, fish, nuts and legumes, and 
lower intake of meats, high fat dairy and sweets 
seem to be associated with lower risk of cognitive 
impairment and dementia [47]. Several studies 
have found a lower risk of dementia is associated 
with higher intake of fruit and vegetables and 
higher adherence to the Mediterranean diet [43]. 
One study of 1433 older people determined that 
6.5% of cases of mild cognitive impairment or 
dementia may be attributable to low fruit and 
vegetable consumption [20]. Another recent 
study found an 88% lower risk of any dementia 
and 92% lower risk of Alzheimer’s disease in 
those with an overall healthy diet at midlife, 
compared to those with an unhealthy diet [48].  
 
There is insufficient evidence to promote specific 
foods for reducing dementia risk, although fish 
and fruits and vegetables show promising 
benefits. The Australian Dietary Guidelines 
recommend avoiding saturated fat and eating 
plenty of fruits and vegetables [49]. This general 
healthy diet is likely to help reduce the risk of 
cognitive decline and dementia, in addition to 
cardiovascular disease and other conditions. 
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4.4 PHYSICAL ACTIVITY 
 
Regular physical exercise is associated with 
better brain function and reduced risk of 
cognitive decline and dementia. This has 
been shown in many studies for exercise 
undertaken in midlife and in late-life. Even 
simple exercise like walking has been shown 
to be beneficial. 
 
4.4.1 Physical activity, cognitive decline and 
dementia risk 
 
There is growing evidence that regular physical 
activity throughout life may protect against 
cognitive decline and dementia in old age. 
However, there is wide variability in the way 
studies measure physical activity and cognitive 
function, and recent reviews have concluded that 
the quality of evidence is low and further 
research is needed to determine the optimal type, 
frequency, duration and intensity of exercise to 
preserve cognitive function [50,51]. Nevertheless, 
it was recently estimated that 13% of cases of 
Alzheimer’s disease are potentially attributable to 
physical inactivity [5]. 
 
Several studies have found that older people who 
exercise regularly are less likely to experience 
cognitive decline or develop dementia. A meta-
analysis of prospective studies found that high 
levels of physical activity were associated with 
38% lower risk of cognitive decline in older 
people without dementia [51]. Even low to 
moderate levels of physical activity were 
associated with 35% lower risk of cognitive 
decline, compared to those who were sedentary. 
A meta-analysis investigating dementia as the 
outcome found a 28% reduced risk of any 
dementia and 45% reduced risk of Alzheimer’s 
disease for those in the highest physical activity 
category compared to the lowest [52]. 
 
Trials of exercise interventions are also providing 
promising results. In a randomised controlled trial 
of people aged 50 and over with subjective 
memory impairment, a 6 month program of 
physical activity resulted in improved cognition at 
the end of the trial and after 18 months follow up 
[53]. 
 
Regular exercise during midlife may also protect 
against later developing dementia. In one study, 
exercising at least twice a week at midlife was 
associated with a 52% reduced risk of dementia 
at age 65-79 [54]. 
 
4.4.2 Physical activity and the brain 
 
Several mechanisms have been proposed to 
explain the association between physical 
inactivity and cognitive decline [51,55,56]. 
 Physical activity helps maintain blood flow to 
the brain and the necessary supply of oxygen 
and nutrients. 
 Physical activity reduces the risk of 
cardiovascular disease, obesity, diabetes, 
high blood pressure high cholesterol and 
cerebrovascular disease. These conditions 
are all associated with increased risk and 
severity of cognitive decline and dementia. 
 Inactivity is associated with higher levels of 
inflammatory markers including C-reactive 
protein. Inflammation in the brain is 
associated with the pathological changes that 
cause cognitive decline and dementia. 
 Physical activity appears to stimulate the 
growth of new neurons and synapses. 
 
Neuroimaging studies have revealed that higher 
levels of physical activity and related better 
cognitive function are associated with larger brain 
volume, including hippocampal volume, and 
increased connectivity between brain regions 
[50]. Physical activity is also associated with 
increased levels of brain-derived neurotrophic 
factor (BDNF) [50], which is involved in 
supporting the survival of existing neurons, the 
growth of new neurons and synapses, and 
learning and memory. 
 
Regular physical exercise provides a range of 
health benefits. The evidence supporting the 
beneficial effects of physical activity on brain 
health provides yet more reasons to encourage 
regular physical activity among people of all 
ages. The National Physical Activity Guidelines 
outline the minimum levels of physical activity 
required to gain a health benefit and ways to 
incorporate physical activity into everyday life 
[57]. 
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5. MODIFIABLE FACTORS – HEART  
 
5.1 BLOOD PRESSURE 
 
High blood pressure (hypertension), 
especially at midlife, is associated with an 
increased risk of developing dementia. 
Treatment of hypertension has been found to 
reduce the risk of cognitive decline and 
dementia in several studies, but this may be 
age dependent. 
 
5.1.1 Blood pressure and dementia risk 
 
Hypertension is a risk factor for cerebrovascular 
disease, stroke, cognitive impairment and 
vascular dementia. Hypertension in midlife may 
also be associated with an increased risk of 
Alzheimer’s disease, however, hypertension in 
old age is not [58-60]. A recent review 
determined that 5% of cases of Alzheimer’s 
disease may be attributable to midlife 
hypertension [5]. 
 
Blood pressure may decline in the preclinical 
stage of Alzheimer’s such that low blood 
pressure in late-life may be associated with 
increased incidence [58-60]. Although, low blood 
pressure may also result in inadequate brain 
blood flow and contribute to cognitive impairment. 
While hypertension in old age does not seem to 
be associated with increased risk of Alzheimer’s 
disease, it has been associated with increased 
risk of cognitive impairment [61]. 
 
The results of clinical trials investigating whether 
treatment with antihypertensive medications 
reduces dementia risk in the elderly have been 
mixed [62]. However, treatment of hypertension 
in early old age has been identified in some 
studies to reduce the risk of cognitive decline and 
dementia. In a 4 year study of 2,400 patients, 
treatment reduced the risk of dementia by 55% 
[63]. 
 
Studies assessing long term use of 
antihypertensives from midlife show a cumulative 
reduction in risk of dementia for each year of 
treatment [58,64]. A study that followed 
hypertensive men from midlife found that for each 
additional year of treatment there was a further 
reduction in the risk of dementia [64]. Those 
treated for more than 12 years had a 60% 
reduced risk of any dementia and 65% reduced 
risk of Alzheimer’s disease compared to those 
never treated. The risk after 12 years of 
treatment was similar to those with normal blood 
pressure [64]. 
 
 
5.1.2 High blood pressure and the brain 
 
Hypertension may contribute to both 
cerebrovascular pathology and Alzheimer’s 
disease pathology [65]. Hypertension may lead to 
dysfunction of the blood vessel lining, mini-
strokes and major stroke. Blood vessel changes 
could also affect the vascular clearance of beta 
amyloid and exacerbate Alzheimer’s disease 
pathology [60,65]. 
 
Cerebrovascular pathology is common in older 
adults, is itself associated with cognitive 
impairment, and often coexists with Alzheimer’s 
disease pathology. Also, for a given level of 
Alzheimer’s pathology, the probability of 
manifesting Alzheimer’s dementia is increased by 
the coexistence of cerebrovascular pathology 
[60,65]. 
 
Hypertension is correlated with higher levels of 
neurofibrillary tangles and amyloid plaques in the 
brain (the pathological hallmarks of Alzheimer’s 
disease). This may be related to findings that 
damage due to restricted blood flow may 
increase beta amyloid production or reduce its 
clearance from the brain [60,65]. Hypertension 
and cerebrovascular disease have also been 
associated with greater hippocampal and cortical 
atrophy, which may be related to loss of neurons 
caused by vascular disease [60,65]. 
 
 
5.2 BODY WEIGHT 
 
Obesity at midlife is associated with an 
increased risk of developing dementia, 
including Alzheimer’s disease. Weight 
reduction has not as yet been shown to 
reduce the risk of dementia. In old age, those 
who are underweight or are losing weight are 
found to be at increased risk of dementia. 
 
5.2.1 Body weight and dementia risk 
 
Obesity, particularly central obesity, at midlife is 
associated with increased risk of later developing 
dementia [38,39]. Midlife obesity has been 
estimated to account for 2% of cases of 
Alzheimer’s disease [5]. Whether midlife weight 
loss for those who are obese can reduce the risk 
of late life dementia has not yet been determined. 
Although, there is clinical trial evidence that 
weight loss lowers blood pressure, improves 
blood lipids and insulin resistance, and positively 
affects other factors associated with 
cardiovascular and dementia risk. 
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Reviews of observational studies found that in 
midlife [39] and early old age (65 to 75 years) 
[38], there is a U-shaped relationship between 
BMI and dementia risk, with increased risk found 
for those who are underweight (BMI < 18.5) as 
well as those who are obese (BMI > 30). A meta-
analysis found that compared to healthy BMI 
(18.5 – 25), obese and underweight BMI in 
midlife are associated with approximately double 
the risk of late life dementia, while overweight 
BMI (25 – 30) increases risk by around one-third 
[39]. 
 
In late life (after 75 years), lower BMI and weight 
loss have been associated with an increased risk 
of dementia [38]. Weight loss may precede 
dementia onset by more than 10 years. A recent 
study of older Australian men found a reduced 
risk of dementia for those in the overweight BMI 
range and no increase in dementia risk for those 
in the obese range [40]. 
 
A recent review summarised the findings of the 
complex relationship between weight and 
dementia across the lifespan as follows [38]: 
 central obesity in middle age predicts 
dementia in old age 
 the relation between obesity and dementia is 
attenuated with older age 
 lower BMI predicts dementia in the elderly 
 weight loss may precede dementia diagnosis 
by decades 
 
5.2.2 Body weight and the brain 
 
There are a number of potential mechanisms by 
which obesity may affect the brain and increase 
dementia risk [38]. Insulin resistance and excess 
insulin can result from obesity and may play a 
role in reducing beta amyloid clearance from the 
brain, increasing the risk of Alzheimer’s disease. 
Adipose tissue produces proteins and hormones 
that are related to excess insulin and 
inflammation that in turn have effects on the 
brain. Obesity is also associated with increased 
risk for high blood pressure, diabetes, 
cardiovascular disease and cerebrovascular 
disease, which affect brain health and increase 
the risk of dementia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3 CHOLESTEROL 
 
High blood total cholesterol, especially at 
midlife, is associated with an increased risk 
of developing dementia, especially 
Alzheimer’s disease. Treatment with statins 
has been found to be associated with reduced 
risk of dementia in several studies, but there 
are some conflicting findings. 
 
5.3.1 Cholesterol and dementia risk 
 
Reviews of studies in this area have concluded 
that high midlife total serum cholesterol is 
associated with an increased risk of any 
dementia and of Alzheimer’s disease [66,67]. 
While there are some studies that have not found 
this association, the majority of studies and meta-
analyses show that high midlife cholesterol 
increases the risk of later developing dementia by 
around 2 times. 
 
A meta-analysis of studies measuring cholesterol 
at late-life and following participants over a few 
years found no association between late life 
cholesterol and dementia risk [67]. Another study 
found that a decrease in cholesterol level from 
midlife to late life was associated with an 
increased risk of Alzheimer’s disease [68]. 
Cholesterol levels may decline in the preclinical 
stages of Alzheimer’s [66,67]. 
 
Several studies have shown reduced risk of 
dementia in those treated with statins [69], but a 
meta-analysis found only a small non-significant 
benefit [70]. It may be that treatment of midlife 
high cholesterol with statins is most beneficial, 
but this has not been examined. 
 
5.3.2 Cholesterol and the brain 
 
Cholesterol plays an essential role in healthy 
brain function [69]. However, some studies 
suggest increased total cholesterol levels are 
involved in the development of Alzheimer’s 
disease [70]. High cholesterol levels may 
accelerate the production of beta amyloid [69,70]. 
Autopsy findings indicate that lower midlife total 
cholesterol is associated with a lower number of 
plaques and tangles [66]. Higher levels of HDL 
(‘good’) cholesterol are associated with larger 
hippocampal volume and reduced risk of 
cognitive impairment and Alzheimer’s disease 
[69]. 
 
Impacts of high total cholesterol levels on 
oxidative stress and on the vascular system may 
also contribute to dementia [69,70]. Untreated 
high total cholesterol can lead to atherosclerosis 
and cerebrovascular disease. 
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5.4 DIABETES 
 
Diabetes is associated with an increased risk 
of developing mild cognitive impairment and 
dementia, including Alzheimer’s disease and 
vascular dementia. The ability of treatment of 
diabetes to reduce dementia risk has not 
been established. 
 
5.4.1 Diabetes and dementia risk 
 
Diabetes, especially type 2, and pre-diabetes 
syndromes appear to be risk factors for cognitive 
impairment and dementia. A recent review 
concluded that type 2 diabetes is associated with 
increased risk of Alzheimer’s disease and 
vascular dementia [71]. Another review reported 
meta-analyses that found diabetes was 
associated with a 47% increased risk of any 
dementia, a 39% increased risk of Alzheimer’s 
disease, and a 138% increased risk of vascular 
dementia [72]. 
 
Diabetes has also been associated with greater 
risk for poorer cognitive function and cognitive 
decline in several studies [14,72]. Global 
cognitive function and executive function have 
been shown to be affected by diabetes. 
 
Few studies have examined the effect of 
treatment of diabetes on dementia risk and the 
results are mixed [72,73]. The effect of the 
duration of diabetes on dementia risk has also 
not been established, however longer duration 
and greater severity have been associated with 
increased risk of cognitive decline [14,72]. 
Prevention of diabetes, through early screening 
for glucose tolerance and insulin resistance and 
lifestyle modifications for those at risk, could 
reduce the incidence of mild cognitive impairment 
and dementia by 5% according to one study [20]. 
Another recent review determined that 2% of 
cases of Alzheimer’s disease could be attributed 
to diabetes [5]. 
 
5.4.2 Diabetes and the brain 
 
Diabetes is a disorder characterised by 
deficiencies in insulin production, response to 
insulin, or both. Insulin resistance, impaired 
insulin secretion, excess insulin and glucose 
intolerance have also been associated with 
increased risk of cognitive impairment and 
dementia [14]. The mechanisms underpinning the 
association between diabetes and dementia risk 
are unclear. Multiple processes may be involved, 
such as the effects of insulin resistance, vascular 
disease, oxidative stress and inflammation [71-
73]. 
 
Insulin-degrading enzyme is involved in the 
clearance of beta amyloid from the brain, which 
may be reduced by excess insulin thus 
increasing the formation of plaques and the risk 
of Alzheimer’s disease [72,73]. Diabetes and pre-
diabetes syndromes can lead to cerebrovascular 
disease and are associated with inflammation 
and oxidative stress, thereby increasing the risk 
of dementia [14,72,73]. 
 
 
5.5 SMOKING 
 
Smoking is associated with an increased risk 
of dementia, including Alzheimer’s disease. 
 
5.5.1 Smoking and dementia risk 
 
Smoking has been demonstrated to be a risk 
factor for dementia. Two recent meta-analyses 
concluded that current smokers have an 
increased risk of any dementia, Alzheimer’s 
disease, vascular dementia and cognitive decline 
compared to non-smokers [74,75]. Another 
review found that 14% of Alzheimer’s disease 
cases may be attributed to smoking [5]. 
 
Former smokers were not found to be at 
increased risk compared to never-smokers, 
suggesting quitting smoking may be beneficial for 
dementia risk [74,75]. 
 
Smoking at midlife has also been associated with 
an increased risk of dementia decades later. A 
prospective study involving over 21,000 people 
found those smoking more than 2 packs a day at 
midlife had more than 2.5 the risk of Alzheimer’s 
disease and vascular dementia compared to non-
smokers [76]. 
 
A recent study examined the association 
between a history of heavy alcohol use and 
smoking and age of disease onset in 685 people 
with Alzheimer's disease. Heavy smoking 
(defined as one pack per day or more) was 
associated with a 2-3 year earlier onset of 
Alzheimer’s disease [77]. 
 
The adverse health effects of exposure to 
secondhand smoke are similar to those of active 
smoking. There is some evidence that passive 
smoking may also be associated with increased 
risk of cognitive impairment and dementia [78]. 
 
5.5.2 Smoking and the brain 
 
Smoking is associated with increased risk for 
cardiovascular and cerebrovascular disease and 
stroke, and with increased oxidative stress, 
atherosclerosis and inflammation. Smoking may 
affect dementia risk via its negative effects on the 
cardiovascular system, increasing risk for both 
Alzheimer’s disease and vascular dementia. 
Smoking may also interact with other 
cardiovascular risk factors in an additive manner 
[74,75].
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6. OTHER POTENTIALLY  
     MODIFIABLE FACTORS 
 
6.1 DEPRESSION 
 
People with a history of depression or high 
depressive symptoms appear to have, on 
average, a higher risk of developing 
dementia. Evidence suggests that treatment 
with antidepressants improves cognition in 
people with depression, but it is not known if 
treatment prevents dementia. 
 
6.1.1 Depression and dementia 
 
A history of depression has been associated with 
an increased risk of Alzheimer’s disease and any 
dementia in several studies [14,79]. Some 
studies, however, have failed to replicate this 
finding. 
 
In a study of 1,953 people with Alzheimer’s 
disease, depressive symptoms before dementia 
onset were twice as common as in controls [80]. 
It may be that early awareness of cognitive 
decline contributes to depression, but it seems 
that this does not fully explain the association. A 
review of epidemiological studies reported a 
history of depression was associated with around 
double the risk of Alzheimer’s disease [81]. 
 
A recent French study of 1433 older people found 
that elimination of depression from the elderly 
population would lead to a 10.3% reduction in 
cases of mild cognitive impairment and dementia 
[20]. Another study likewise concluded that 
around 10% of cases of Alzheimer’s disease may 
be attributable to depression [5]. 
 
It is well known that people with depression, 
especially older adults, have reduced cognitive 
performance and that many people with dementia 
also have depression. It is therefore difficult to 
determine whether depression is a risk factor for 
dementia or whether it is a prodromal symptom 
or both [14,79].  A review of studies found that 
the interval between diagnoses of depression 
and Alzheimer’s disease was positively related to 
increased risk of developing Alzheimer’s, 
suggesting that depression is likely a risk factor 
[81]. 
 
Other mental disorders may also be associated 
with increased dementia risk. In a recent study of 
predominantly male war veterans, those 
diagnosed with post-traumatic stress disorder 
(PTSD) were at nearly twice the risk of 
developing dementia compared with those 
without PTSD [82]. 
 
6.1.2 Depression and the brain 
 
Depression is associated with elevated cortisol 
production, which may directly damage the 
hippocampus and increase the risk of dementia 
[20,79]. Conversely, depression may arise 
secondary to dementia due to frontostriatal 
damage from cerebrovascular or Alzheimer’s 
pathology [14,79]. Recent studies have also 
suggested that people with depression have 
enhanced deposition of beta amyloid plaques 
[79]. Depression has been associated with 
inflammation and vascular changes in the brain, 
which may also contribute to cognitive 
impairment and dementia [5,14]. 
 
The treatment of depression seems to improve 
cognitive function, but it may not return cognition 
to normal levels even when the depression is in 
remission [14,79]. Whether the treatment of 
depression decreases the risk of dementia 
among people with depressive symptoms has not 
yet been studied, but it is clearly important to 
identify and treat depression. Treating depression 
may slow functional loss in those with cognitive 
impairment and preventing new episodes of 
depression may be a useful preventative 
approach to dementia [20,83]. 
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6.2 HEAD INJURY 
 
Serious head injury, with loss of 
consciousness, is associated with an 
increased risk of subsequent cognitive 
decline and dementia. 
 
6.2.1 Head injury and dementia 
 
Several studies have examined the association 
between head injury and risk of dementia in late-
life. Head injury has been shown to increase the 
risk of cognitive decline, dementia and 
Alzheimer’s disease [14]. The association may be 
mediated by the severity of head injury, whether 
loss of consciousness occurs, the time between 
head injury and dementia onset and genetic 
factors [14]. 
 
Long term follow up of US World War II veterans 
who were admitted to hospital during service 
showed that those who had suffered a head 
injury with loss of consciousness had an 
increased risk of subsequently developing 
Alzheimer’s disease compared to those admitted 
for other reasons [84]. Those with moderate head 
injuries had 2.3 times the risk and those with 
severe head injuries had 4.5 times the risk. 
 
A meta-analysis of studies found a 58% 
increased risk of Alzheimer’s disease for those 
with a history of serious head injury [85]. The 
association was found to be significant only in 
males (possibly because they make up the 
majority of study participants). A more recent 
review concluded that moderate and severe head 
injuries increase the risk of dementia by 2 to 4 
times [86]. 
 
Multiple mild head traumas as experienced by 
boxers are associated with a high risk of chronic 
traumatic encephalopathy (CTE), a type of 
dementia with distinct clinical and pathological 
features [86]. Recent research suggests that CTE 
may also be common in football players and 
military personnel. However, it is less clear 
whether repeated mild injuries such as brief 
concussions result in increased risk of the more 
common forms of dementia including Alzheimer’s 
disease [86].  
 
Several mechanisms have been proposed to 
explain the association between head injury and 
increased dementia risk. Damage to the blood 
brain barrier, increased oxidative stress, neuronal 
loss, increased enzyme activity leading to 
increased beta-amyloid deposition and increased 
tau pathology have all been implicated [14]. 
 
 
 
  14 
7. MYTHS, CONTROVERSIES  
     AND POSSIBILITIES 
 
7.1 ALUMINIUM 
 
Excessive aluminium exposure is neurotoxic and 
may cause cognitive impairment. In the 
Camelford water incident, which occurred in 1988 
in the UK, 20 tonnes of aluminium sulphate 
contaminated a town’s drinking supply and 
exposed people were reported to have 
subsequently suffered cognitive deficits, but not 
increased rates of dementia [87]. However, the 
methodology of this study was criticised, and a 
2005 inquiry concluded it is unlikely the incident 
caused any long term health effects [88]. 
 
Aluminium is the third most common element on 
earth and we are exposed to it from many 
environmental sources including in water, 
cooking utensils, polluted air and deodorants. 
Some studies have found higher levels of 
aluminium in drinking water, or measured in 
blood samples, are associated with an increased 
incidence of dementia, but many studies have 
failed to show any association. A recent review 
concluded there is only weak evidence that a 
higher risk of Alzheimer’s disease is associated 
with high aluminium intake through drinking water 
[89]. It is likely only abnormally high levels pose 
any risk and there is no danger from the typical 
levels of aluminium in the environment, cooking 
utensils or deodorants. 
 
No trials have yet looked at whether there are 
potential benefits of reducing aluminium intake, 
and at this stage there is no evidence to support 
avoidance of aluminium to prevent dementia. 
 
 
7.2 CAFFEINE 
 
Some studies of coffee and tea consumption 
suggest a possible protective effect for caffeine. 
A small study in Portugal found those with 
Alzheimer’s disease had a lower average 
caffeine intake over the previous 20 years 
compared to healthy controls (74mg per day 
compared to 200mg per day) [90]. A more recent 
study in 7017 French people over 65 found that 
women who drank 3 or more cups of coffee per 
day showed less cognitive decline over 4 years 
than those consuming 1 cup or less [91]. 
However, no association was found between 
caffeine consumption and cognitive decline in 
men, or between caffeine intake and risk of 
dementia for either gender. 
Another study however did find an association 
between higher caffeine consumption and lower 
dementia risk [92]. 
 
The potential beneficial effects of caffeine may be 
through mechanisms that reduce beta amyloid 
production or increase the level of brain proteins 
important for learning and memory such as brain 
derived neurotrophic factor (BDNF) [14]. 
 
At this stage increasing caffeine intake, which 
may cause other health problems, with the aim of 
reducing dementia risk cannot be recommended. 
 
 
7.3 GENERAL ANAESTHESIA 
 
Long-term cognitive problems have been 
reported in older adults following surgery with 
general anaesthesia, suggesting that exposure to 
anaesthesia may increase the risk of cognitive 
impairment and dementia [14]. Some animal and 
laboratory studies suggest that anaesthetic 
agents can increase the production and 
aggregation of beta amyloid, increasing the risk 
of Alzheimer’s disease [93]. However, findings 
from human studies do not support an 
association [14,93]. A few studies suggest a 
possible increased risk of dementia after surgery 
with general anaesthetic, while others show no 
association, and some suggest a reduced risk of 
dementia with a history of exposure to 
anaesthesia. Studies also show that the type of 
surgery (major or minor) and type of anaesthesia 
(general or regional) make no difference to the 
long-term cognitive outcomes for older patients 
[93]. 
 
A meeting of international experts in 2009 
concluded that there is not enough evidence to 
avoid the use of anaesthesia on the basis that it 
might lead to Alzheimer’s disease [93]. 
 
Postoperative cognitive dysfunction (POCD) is 
the term used to describe cognitive problems 
following surgery. We now know that POCD 
occurs in the elderly not only after major surgery, 
but even after minor procedures with sedation 
[93]. This may represent an unmasking of 
cognitive impairment that was developing 
anyway, due to underlying brain disease such as 
Alzheimer’s, rather than any causal link with the 
anaesthetic or surgery. 
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At present, there is scarce information on 
whether anaesthesia and surgery can exacerbate 
existing Alzheimer’s disease, dementia or mild 
cognitive impairment [93]. This possibility though 
suggests that non-urgent surgery should be 
carefully considered for people with these 
conditions. 
 
More research is needed to determine the long-
term impacts of anaesthetic agents on the brain 
and cognitive function. 
 
 
7.4 GINKGO BILOBA 
 
Ginkgo biloba is a tree, native to China. Extracts 
of ginkgo leaves are believed to have antioxidant 
properties and effects on neurotransmitters, and 
to increase brain blood flow, and are marketed as 
enhancers of memory and concentration. 
However, clinical trials of ginkgo’s efficacy as a 
cognitive enhancer have produced inconsistent 
findings. 
 
Several clinical trials have investigated ginkgo as 
a potential treatment for cognitive impairment, 
dementia or Alzheimer’s disease, but most have 
been small studies of short duration. A recent 
review found nine trials of six months duration 
including 2016 participants [94]. These trials 
showed inconsistent results for cognition, 
activities of daily living, mood, depression and 
carer burden. The reviewers concluded that there 
is no convincing evidence that ginkgo is effective 
as a treatment for cognitive impairment or 
dementia [94]. However, some studies have 
demonstrated beneficial effects, so further 
research is warranted. 
 
Fewer clinical trials have investigated ginkgo’s 
potential to prevent dementia. The largest study 
reported to date was a randomised clinical trial in 
3069 adults aged 75 and older, with normal 
cognitive function or mild cognitive impairment, 
followed up over 6 years. This study found ginkgo 
showed no benefit for reducing incidence of any 
dementia or Alzheimer’s disease [95]. 
 
In June 2011 an expert meeting "The Ageing 
Brain" took place in Amsterdam, The 
Netherlands. The aim was to discuss the 
available evidence on ginkgo and cognitive 
decline and Alzheimer's disease. The participants 
concluded that there is enough promising data, 
both preclinical and clinical, to undertake further 
research with gingko to target cognitive 
impairment in old age [96]. 
 
Adverse effects of ginkgo can include headache, 
gastrointestinal symptoms and allergic skin 
reactions. It can also increase bleeding, 
especially when used in combination with other 
agents that may increase bleeding, such as 
aspirin or warfarin. 
 
Based on the evidence to date, ginkgo biloba 
cannot be recommended for preventing or 
treating cognitive impairment or dementia, but 
research is continuing. 
 
 
7.5 INFLAMMATION AND ANTI-
INFLAMMATORY MEDICATIONS 
 
Inflammation is known to play a role in the 
pathological brain changes and brain cell death 
that cause dementia [14,97]. Therefore, studies 
have investigated whether inflammatory 
biomarkers are associated with increased risk of 
dementia, and the potential for anti-inflammatory 
drugs to reduce the risk. 
 
Levels of indicators of inflammation (including C-
reactive protein) can be measured in the blood. 
Findings from studies of whether elevated blood 
levels of inflammatory markers are associated 
with increased risk of cognitive decline or 
dementia have been inconsistent. A review 
concluded that these studies do not provide 
consistent support for an association between 
elevated inflammatory markers and risk for 
Alzheimer’s disease, but associations between 
higher levels of inflammatory markers and risk for 
any dementia are more suggestive, consistent 
with a reported link between inflammation and 
vascular dementia [97]. Part of the reason for the 
lack of a convincing association may be that 
inflammatory markers measured in blood may not 
accurately reflect inflammation in the brain. 
Future research may provide more clarity by 
measuring brain-specific markers of inflammation 
[97]. 
 
Observational studies have demonstrated 
support for a protective effect of non-steroidal 
anti-inflammatory drugs (NSAIDs), finding a 
history of use is associated with reduced risk of 
dementia [14,98]. In a meta-analysis of 9 studies, 
with over 13,000 people, the risk of Alzheimer’s 
disease amongst users of NSAIDs was 28% less 
than in non-users, and 73% less in those who 
had used such drugs for over 24 months [99]. 
However, randomised controlled trials have not 
found similar protective effects [14]. Possible 
reasons for the discrepancy include differences in 
the timing, type and dose of NSAID treatment 
[100]. One observational study reported a slower 
rate of cognitive decline when NSAID use began 
in midlife compared to late-life [101]. 
 
NSAIDs can have significant side effects and 
there is insufficient evidence to recommend their 
use for reducing dementia risk. 
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7.6 OESTROGEN AND HORMONE 
REPLACEMENT THERAPY 
 
Observational studies of postmenopausal 
hormone replacement therapy (HRT) suggest 
that it may reduce risk of cognitive decline and 
dementia [102,103]. The association appears 
strongest for Alzheimer’s disease [103]. 
However, results from a randomised controlled 
trial as part of the Women’s Health Initiative 
Memory Study reported no benefit to cognitive 
function or risk of mild cognitive impairment, and 
an increased risk of dementia [104]. The 
important difference in this study was that it 
involved women aged 65 years or older, whereas 
the observational studies investigated HRT use 
at middle age. HRT may still benefit cognitive 
health if started in women at and soon after 
menopause. A review concluded that early 
initiation of HRT at menopause may provide 
cognitive benefits, while HRT initiated in late life 
may have detrimental effects [105].  More 
conclusive evidence is needed before HRT can 
be recommended as a strategy to reduce the risk 
of cognitive impairment or dementia [14]. 
 
The brain has oestrogen receptors, and 
oestrogen affects brain blood flow and levels of 
neurotransmitters important for memory. 
Oestrogen has also been shown to have 
neuroprotective effects including stimulating the 
growth of new neurons and supporting neurons 
involved in learning and memory, and reducing 
the production of beta amyloid and protecting 
against its toxic effects [103]. Oestrogen may 
improve memory in women without cognitive 
problems but not all studies have confirmed this 
[106]. 
 
HRT should not be taken specifically to reduce 
the risk of dementia, but if it is needed to alleviate 
postmenopausal symptoms during midlife, it is 
unlikely to have any detrimental effects on 
women’s late life cognitive health. 
 
 
7.7 STRESS 
 
Studies of rats showed that extreme chronic 
stress may damage the hippocampus, a brain 
structure crucial for memory and learning [107]. 
This gave rise to a hypothesis that chronic stress 
and raised cortisol levels in humans may 
increase the risk of Alzheimer’s disease. 
However, this has not been supported by 
subsequent research. Smaller hippocampal 
volumes have been associated with poor 
cognitive function and increased risk of dementia 
[108]. But recent post-mortem studies have failed 
to find a relationship between chronic stress or 
cortisol levels and Alzheimer’s disease pathology 
in the brain or hippocampal atrophy 
[107,109,110]. In addition, recent animal studies 
have failed to find substantial neuronal loss in the 
hippocampus following exposure to chronic 
stress. A recent review concluded that there are 
no convincing arguments to presume a causal 
role for cortisol in the development of Alzheimer’s 
disease pathology [107]. 
 
Several studies have investigated the potential 
relationship between stress and risk for 
dementia, by assessing personality traits that 
make people more prone to psychological 
distress. Higher proneness to stress has been 
associated with increased risk of mild cognitive 
impairment [111], increased risk of dementia and 
Alzheimer’s disease [109,110,112], and more 
rapid cognitive decline [110]. A study in Swedish 
twins found that measures of work-related stress 
at midlife were not associated with later dementia 
risk, but greater reactivity to stress was 
associated with an increased dementia risk [113]. 
It appears that exposure to stress per se may not 
be associated with dementia, and is not 
associated with the pathology of Alzheimer’s 
disease, but personality characteristics that make 
people more vulnerable to stress may be 
associated with increased dementia risk. 
 
 
7.8 TESTOSTERONE 
 
The brain has testosterone receptors, including in 
regions important for memory and learning such 
as the hippocampus. Testosterone has also been 
shown to have beneficial actions supporting 
neurons and synapses [114]. Testosterone levels 
in men and women reduce with ageing, but more 
markedly in men. 
 
Several studies have reported that compared to 
healthy older men, men with Alzheimer's disease 
and other dementias have lower serum 
testosterone levels [115]. Lower testosterone 
levels have also been associated with greater 
risk of Alzheimer’s disease, mild cognitive 
impairment and cognitive decline [116,117], and 
increased levels of beta amyloid in the brain 
[118]. Animal studies have shown that 
testosterone depletion results in increased levels 
of beta amyloid and hyperphosphorylated tau, the 
pathological hallmarks of Alzheimer’s disease 
[117]. Some studies suggest that testosterone 
supplementation may improve cognitive 
performance and reduce beta amyloid levels 
[115,119]. 
 
Taken together, these findings suggest that the 
reduction in testosterone during ageing could 
contribute to the development of Alzheimer's 
disease, and that testosterone supplementation 
could assist in the prevention or treatment of 
cognitive decline and dementia. 
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However, more research is needed to determine 
the factors that influence the optimal level of 
testosterone for maintaining cognitive function 
with ageing, and whether long term testosterone 
therapy is safe and effective. 
 
Alzheimer’s researchers in Perth are 
investigating the role of testosterone in beta 
amyloid production and assessing testosterone 
replacement therapy in animal and human 
studies as a potential treatment for Alzheimer's 
disease [120]. A long term study will assess the 
efficacy of testosterone at lowering beta amyloid 
and improving memory. 
 
 
7.9 VITAMIN D 
 
It is well known that vitamin D deficiency can 
affect bone health, and it may also be linked with 
heart disease, some cancers and diabetes. Blood 
levels of vitamin D reflect synthesis from 
exposure to sunlight as well as intake from the 
diet. Most adults are unlikely to obtain more than 
5-10% of their vitamin D requirement from dietary 
sources, with the main source being exposure to 
sunlight [121]. Vitamin D deficiency affects 31% 
of adult Australians and increases significantly 
with age [122]. The groups at greatest risk of 
vitamin D deficiency include housebound older or 
disabled people, those in residential care, dark-
skinned people, and others who regularly avoid 
sun exposure or work indoors [121]. Of course, 
adequate sun exposure to maintain healthy 
vitamin D levels has to be weighed against the 
risk of skin cancer. 
 
Vitamin D deficiency may also be associated with 
increased risk of cognitive impairment or 
dementia. A recent meta-analysis of 7 studies 
comprising 7,688 participants showed a 2.4 times 
increased risk of cognitive impairment in those 
with low vitamin D compared with normal vitamin 
D [123]. In a study of 318 people aged 65 and 
over, vitamin D deficiency was associated with 
increased risk of dementia, stroke and 
cerebrovascular disease [124]. However, there 
are some conflicting findings and methodological 
issues between studies including different ways 
of measuring vitamin D deficiency and cognitive 
function, so more research is needed. It is also 
not known whether vitamin D supplementation 
can reduce the risk of cognitive decline or 
dementia. 
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8. PREVENTATIVE STRATEGIES FOR    
     THOSE DIAGNOSED WITH DEMENTIA 
 
Many of the preventative strategies 
addressed in Alzheimer’s Australia’s Your 
Brain Matters program are also likely to 
benefit people diagnosed with dementia. 
Remaining active and socially engaged, 
treating depression and managing 
cardiovascular risk factors may help slow the 
progression of cognitive decline in those with 
dementia. 
 
Management of dementia should include 
preventative approaches to maintain health and 
wellbeing as much as possible. The management 
of comorbid conditions may have to be modified 
in the presence of dementia according to the 
person's declining ability to self-manage their 
healthcare. 
 
Drugs with anticholinergic effects can worsen 
cognition in those with Alzheimer’s disease and 
may blunt the effects of cholinesterase inhibitors 
[125]. Their use should be minimised in people 
with Alzheimer’s disease and other dementias. 
 
 
8.1 DEPRESSION 
 
Depression is a common comorbidity in dementia 
and is itself associated with cognitive impairment. 
Continuous antidepressant use has been 
associated with a reduced rate of cognitive 
decline in people with depression and 
Alzheimer’s disease, compared to non-depressed 
and untreated depressed people with Alzheimer’s 
[126]. Depression has also been identified as a 
risk factor for early transition to residential care in 
people with dementia, with antidepressant 
treatment seeming to protect against this 
outcome [127]. 
 
Depression has consequences detrimental to 
people with dementia and should be managed 
with appropriate behavioural and/or 
pharmacological treatments, with careful 
monitoring to determine effectiveness and any 
adverse effects [8]. 
 
 
8.2 VASCULAR RISK FACTORS 
 
Careful treatment of hypertension (while avoiding 
episodes of low blood pressure), high cholesterol 
and diabetes (particularly avoidance of 
hypoglycemia) is recommended for those with 
vascular dementia [8]. It is likely to also be 
important for people with other forms of dementia 
including Alzheimer’s disease. 
Treating hypertension, high cholesterol and 
diabetes has been associated with slower 
progression of dementia. For people with 
Alzheimer’s disease without cardiovascular 
disease, vascular risk factor treatment was 
associated with significantly less cognitive 
decline over an average follow up time of 2.3 
years [128]. In this study, only 7% of the 
Alzheimer’s disease patients had no vascular risk 
factors, suggesting they are common in the 
dementia population. Neuroimaging studies have 
also demonstrated benefits of vascular risk factor 
treatment in people with dementia, such as 
slowed progression of white matter lesions [129]. 
 
 
8.3 MENTAL STIMULATION 
 
There is ongoing research to determine whether 
cognitive training can improve, maintain or slow 
decline of cognitive function in dementia. A meta-
analysis of the literature on cognitive training for 
people with Alzheimer’s disease concluded that it 
may improve cognitive and functional abilities, or 
at least slow the rate of decline [130]. 
 
Cognitive rehabilitation programs that focus on 
real life activities and provide education to 
improve self-management, rather than training 
specific cognitive skills, may be more beneficial 
[25]. 
 
There is also evidence that cognitive and 
functional decline in dementia may be delayed by 
continued participation in mentally stimulating 
activities [8,131]. People with dementia should be 
encouraged, as far as possible, to maintain their 
usual hobbies and activities. While adjustments 
may be needed as dementia progresses, keeping 
socially involved and mentally active may be 
important for the person’s cognitive and 
functional status and mental wellbeing. 
 
 
8.4 PHYSICAL ACTIVITY 
 
There is good evidence to recommend an 
individualised exercise program for people with 
mild to moderate dementia [131]. Benefits include 
increased strength, fitness, and improvements in 
cognitive and functional performance [132]. A 
randomised controlled trial of nursing home 
residents with Alzheimer’s disease reported that 
a simple exercise program (1 hour twice a week), 
compared with routine medical care, was 
associated with slower functional decline [133]. 
  19
An Australian randomised controlled trial of older 
people with subjective memory complaints found 
that a six month physical activity intervention 
improved cognition over 18 months follow up 
[53]. This trial is currently being repeated in 
patients with Alzheimer’s disease. 
 
Physical exercise should be continued for as long 
as possible for people with dementia as it can 
help prevent muscle weakness, mobility 
problems, falls and other health complications. It 
may also help promote a normal day-night 
routine, improve mood, increase social 
participation and reduce stress and depression. 
 
 
8.5 DIET 
 
Eating a well balanced diet can be beneficial for 
those with dementia, giving the person more 
energy and helping to avoid health problems. 
Eating or drinking too little or missing out on 
essential nutrients can increase confusion. 
Special attention needs to be paid to avoid or 
deal with obesity or loss of weight, to ensure an 
adequate dietary intake of vitamins and minerals, 
and to avoid dehydration [8]. 
 
Higher adherence to the Mediterranean diet has 
been associated with lower mortality in people 
with Alzheimer’s disease [134]. For each 
additional point on an adherence scale of 0 to 9, 
patients had a 24% lower risk of dying over 4.4 
years of follow up, suggesting a dose-response 
effect. A balanced diet low in saturated fat and 
high in vegetables and fruit may increase survival 
in patients with dementia. 
 
Souvenaid is a medical food, taken as a daily 
drink, which contains a patented combination of 
nutrients and aims to improve synapse formation 
and function. Recent clinical trial results suggest 
that it improves memory performance and brain 
functional connectivity in people with mild 
Alzheimer’s disease [135]. It is currently being 
tested in people with prodromal Alzheimer’s 
disease. Souvenaid is not yet approved or 
available for use as a therapy for Alzheimer’s 
disease. 
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9. STATE OF THE SCIENCE 
 
9.1 THE NATIONAL INSTITUTES OF HEALTH 
EVIDENCE REPORT 
 
The American National Institutes of Health (NIH) 
commissioned a panel of experts to review 
published literature on the factors associated with 
the reduction of risk of Alzheimer’s disease and 
determine whether recommendations for 
interventions could be made. The panel 
concluded that “firm conclusions simply cannot 
be drawn about the association of any modifiable 
risk factor with Alzheimer’s disease” [136], noting 
further research efforts need to be increased 
[136-138]. 
 
At first glance, the panel’s report may seem to 
contradict the substantial research that has been 
carried out to date on the risk and protective 
factors of Alzheimer’s disease and other forms of 
dementia. However, this is not necessarily the 
case. The panel based their conclusions partly on 
a lack of randomised controlled trials (RCTs) – 
the most rigorous, highest quality evidence. 
Undertaking RCTs for dementia prevention and 
risk reduction research is problematic, from an 
ethical and pragmatic perspective. For example, 
to prove that treating midlife high cholesterol 
reduces Alzheimer’s disease risk, researchers 
could not ethically apply treatment over an 
extended period of time, to one group and not 
another, because high cholesterol is a known risk 
factor for  other conditions and needs to be 
treated. 
 
Further, Qiu and colleagues [139], in their 
response to the NIH report, argued that the 
evidence was not evaluated from a life-course 
perspective. That is, the effect of certain risk 
factors on the risk for Alzheimer’s disease largely 
depends on age. For example, elevated blood 
pressure in young and middle age is associated 
with a greater risk of Alzheimer’s disease, while 
low blood pressure (rather than elevated blood 
pressure) in later life is associated with an 
increase in the risk of Alzheimer’s disease. Qiu 
and colleagues point out that the evidence 
supporting these age-dependent risk factors is 
usually found in population-based long-term 
follow-up studies, rather than RCTs, which tend 
to be conducted only with elderly participants 
[139]. 
 
The NIH report was also criticised for focusing on 
Alzheimer’s disease, when the growing numbers 
of people of advanced age underlie the looming 
increase in the number of people with dementia, 
and many of these people will have a mixed 
pathology [140]. Flicker and colleagues also 
criticised the report for not including a broader 
range of studies in their review and for being far 
too negative about the available evidence for 
modification of lifestyle factors to have an impact 
on reducing dementia incidence [140].  
 
Additionally, the NIH report acknowledged that 
there are a number of modifiable factors that 
have an association with risk for Alzheimer’s 
disease and/or cognitive decline. These include 
diabetes, high cholesterol in midlife, depression, 
dietary factors, educational attainment, cognitive 
engagement, smoking and participation in 
physical activities [136-139]. 
 
In summary, whilst the evidence for dementia 
prevention is as yet inconclusive, there is a 
growing body of evidence that shows great 
promise. The NIH report noted the need for long 
term population-based studies that follow 
individuals from midlife into old age to determine 
how biological, lifestyle, dietary, clinical and 
socioeconomic factors may influence Alzheimer’s 
disease [136-139]. 
 
In the meantime, the community must be 
informed of existing evidence-based strategies, 
such as those presented in Alzheimer’s 
Australia’s Your Brain Matters program, to 
increase awareness and promote a ‘brain 
healthy’ lifestyle that will also be of benefit in 
addressing a number of other chronic diseases. 
 
 
9.2 OTHER EVIDENCE REVIEWS 
 
There have been a number of comprehensive 
review papers published in the last few years, 
detailing not only the evidence obtained from 
RCTs, but also from observational research. 
There is a positive consensus from these reviews 
that we can and should continue to examine 
these modifiable risk factors and promote their 
potential to reduce the risk of dementia. 
 
Middleton and Yaffe [79,141] proposed that 
population-based studies have identified a 
number of modifiable lifestyle factors that may 
increase the risk of dementia. These include 
vascular risk factors (diabetes, high blood 
pressure, high cholesterol and obesity), lack of 
cognitive stimulation, physical inactivity, social 
isolation, poor diet and depression. However, 
they concede that RCTs have been less 
conclusive and more work is required. 
Particularly, Middleton and Yaffe advocate the 
importance of examining multiple risk factors 
concurrently in future RCTs, in order to determine 
how we might combine interventions to best 
reduce dementia risk [79,141]. 
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Hughes and Ganguli [14] also reviewed the 
evidence for modifiable risk factors for dementia 
and again highlighted that most of the supporting 
evidence comes from cross-sectional or 
observational studies. They proposed that in 
addition to RCTs, observational studies designed 
with the life-course perspective in mind are also 
required, as the majority of studies to date have 
relatively short follow-up periods [14]. 
 
Barnes and Yaffe [5] projected the effect of seven 
modifiable risk factors (diabetes, elevated blood 
pressure in midlife, midlife obesity, smoking, 
depression, cognitive stimulation and physical 
activity) on the prevalence of Alzheimer’s 
disease. They concluded that up to half of 
Alzheimer’s disease cases worldwide may be 
attributable to these risk factors, and that if risk 
factor prevalence were 25% lower, there would 
be three million fewer cases of Alzheimer’s 
disease throughout the world. This presents a 
compelling argument for continuing to strengthen 
the research evidence in this field. 
 
Reviewers in the cardiovascular field are also 
discussing the contribution of modifiable vascular 
risk factors to the development of Alzheimer’s 
disease, cognitive impairment and dementia 
[142-145]. They conclude that cardiovascular 
conditions are associated with increased risk for 
Alzheimer’s disease and offer opportunities for 
preventative intervention [143,145]. They 
recommend that the best time to intervene is in 
midlife and early old age, and that studies 
addressing multiple risk factors are required 
[142,143,145]. They also suggest capitalising on 
people’s concerns about developing dementia to 
improve adherence to long term lifestyle changes 
and medications to treat their cardiovascular risk 
factors [144]. 
 
In sum, the evidence base for a number of 
modifiable dementia risk factors is growing, and 
more research is required. In particular, studies 
examining multiple risk factors, and studies 
considering both midlife and late-life risk factors, 
are most urgently needed. 
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10. CURRENT AND FUTURE RESEARCH 
 
10.1 LIFESTYLE STUDIES 
 
The research projects listed below are just 
some of the studies currently underway, 
which over the next few years will provide 
improved knowledge about lifestyle 
interventions that may influence cognitive 
health and dementia risk. 
 
10.1.1 Australian studies 
 
The Study of Mental Activity and Resistance 
Training (SMART Trial) aims to determine 
whether increased mental and physical activity 
can prevent cognitive impairment or dementia. It 
is being conducted by ageing and exercise 
researchers in Sydney. The SMART Trial 
involves older individuals with borderline 
cognitive abilities who are therefore at risk of 
developing dementia. Participants complete 
supervised cognitive and/or physical training for 
six months and undergo longitudinal outcome 
assessments 12 months later. The study will test 
whether any benefits to mental function are a 
result of changes in brain structure and function, 
body metabolism, biochemistry and immune 
function. For more information, visit the SMART 
Trial website at 
http://www.med.unsw.edu.au/PSYCHWeb.nsf/pa
ge/brainage_SMART. 
 
The Australian Imaging Biomarkers and 
Lifestyle Flagship Study of Ageing (AIBL) 
aims to improve our understanding of the causes 
of Alzheimer's disease, and help develop 
improved diagnostic methods and preventative 
strategies. It is a longitudinal study of ageing 
involving over 1000 volunteers with Alzheimer's 
disease, mild cognitive impairment, and healthy 
older people. The study is being conducted by 
Alzheimer’s researchers in Melbourne and Perth. 
The study involves cognitive testing, blood tests, 
brain imaging and measures of lifestyle such as 
diet and levels of physical activity. It will help 
researchers develop and confirm diagnostic 
markers of Alzheimer’s disease that can be used 
to diagnose dementia early and monitor disease 
progression. The researchers will also develop 
hypotheses about diet and lifestyle factors that 
might delay the onset of dementia. This will 
enable studies that may lead to clinically proven 
preventative strategies for Alzheimer's disease to 
be designed and conducted. This includes a 
current trial to establish whether physical activity 
can delay progression of cerebrovascular 
disease in older adults with memory complaints 
or mild cognitive impairment and at least one 
cardiovascular risk factor. For further information, 
visit the AIBL website at http://www.aibl.csiro.au. 
 
The Personality and Total Health (PATH) 
Through Life project aims to track and define the 
lifespan course of depression, anxiety, substance 
use and cognitive ability, to identify 
environmental risk and protective factors 
influencing these characteristics, and to examine 
the relationships over time between depression, 
anxiety and substance use with cognitive ability 
and dementia. PATH is a 20 year longitudinal 
study involving 7,485 young (aged 20–24 at 
baseline), middle aged (aged 40–44 at baseline) 
and older (aged 60–64 at baseline) adults. It is 
being conducted by ageing researchers at the 
Australian National University in Canberra. The 
fourth wave of data collection is currently 
underway. Findings to date include that 
cerebrovascular disease is present in midlife and 
associated with cognitive deficits, suggesting that 
preventative strategies should, therefore, begin 
early in life [146]. For further information, visit the 
Centre for Research on Ageing, Health and 
Wellbeing website at 
http://crahw.anu.edu.au/research/projects/person
ality-total-health-path-through-life.  
 
The Body, Brain, Life (BBL) project is 
investigating a novel online intervention to assist 
middle aged individuals at risk of dementia 
achieve and sustain changes in several lifestyle 
areas. It is being conducted by ageing 
researchers at the Australian National University 
in Canberra. A risk assessment tool has been 
developed based on the evidence for the impact 
of different risk factors for Alzheimer’s disease. 
The efficacy of the BBL program is being 
evaluated via a randomised controlled trial. If 
shown to be successful, it has the potential to be 
implemented as an accessible online intervention 
in the Australian community, and to contribute to 
the reduction of the prevalence of dementia risk 
factors in the wider community. For further 
information, visit the Centre for Research on 
Ageing, Health and Wellbeing website at 
http://crahw.anu.edu.au/research/projects/body-
brain-life. 
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The Fitness for the Ageing Brain Study II 
(FABS II) aims to establish whether physical 
activity can decrease the rate of cognitive decline 
among people with mild to moderate Alzheimer’s 
disease. The project is being led by researchers 
at the National Ageing Research Institute in 
Melbourne. Previously, the researchers 
successfully developed an exercise program for 
people with mild cognitive impairment (FABS). 
The intervention provided a modest improvement 
in cognition compared to usual care [53]. The 
program has also been tested in a pilot study with 
people with mild to moderate Alzheimer’s, which 
found less cognitive decline in the intervention 
group. Should this be confirmed in the larger 
study, a program of physical activity would have 
the potential benefit of providing an affordable 
and relatively simple intervention. 
Delaying deterioration in people with Alzheimer’s 
disease may postpone disability, prolong 
independent living and potentially reduce the 
costs associated with care. For further 
information, visit the National Ageing Research 
Institute website at 
http://www.mednwh.unimelb.edu.au/research/de
mentia.htm.  
 
10.1.2 International intervention trials 
 
The Prevention of Dementia by Intensive 
Vascular Care (preDIVA) trial aims to determine 
whether treatment of cardiovascular risk factors 
in elderly people reduces the risk of dementia. It 
is a large, multi-centre Dutch trial, with 3,700 
participants aged between 70 and 78 years of 
age. The preDIVA intervention includes the 
treatment of hypertension, high cholesterol and 
diabetes, as well as focusing on reducing 
overweight, smoking cessation and stimulating 
physical exercise. The study duration is six years, 
and it will test whether the intervention leads to a 
decrease in dementia. For more information on 
the preDIVA trial, visit http://www.controlled-
trials.com/ISRCTN29711771/prediva. 
 
 
 
 
 
 
 
 
 
 
The Finnish Geriatric Intervention Study to 
Prevent Cognitive Impairment and Disability 
(FINGER) is a multi-domain intervention that 
aims to prevent cognitive impairment and 
dementia. It is a large, multi-centre trial, located 
at six sites across Finland, and involves 1,200 
participants from 60 to 77 years of age. Over two 
years, participants will be given lifestyle 
interventions including nutritional guidance, 
exercise, cognitive training, increased social 
activity, and monitoring and management of 
metabolic and vascular risk factors such as 
hypertension, high cholesterol, obesity and 
impaired glucose tolerance. The participants will 
be followed up over seven years to determine 
whether the intervention reduces the risk of 
cognitive impairment and dementia. For more 
information on the FINGER trial, visit 
http://www.clinicaltrials.gov/ct2/show/NCT010419
89?id=NCT01041989&rank=1. 
 
The Multidomain Alzheimer Preventive Trial 
(MAPT) aims to evaluate the efficacy of three 
interventions over a three year period. The 
French trial includes 1680 participants aged 70 
years and over. The first intervention involves 
supplementation with omega-3 fatty acids; the 
second involves a multi-domain intervention 
which focuses on nutrition, physical exercise, 
cognitive stimulation and social activities. The 
third intervention is a combination of the first two 
interventions. The participants will be followed up 
over five years, and the study aims to measure 
any changes in cognitive function over this time. 
For more information on the MAPT trial, visit 
http://www.clinicaltrials.gov/ct2/show/NCT006726
85?term=MAPT+toulouse&rank=1. 
 
The Impact of Nutritional Lipids on Neuronal 
and Cognitive Performance in Aging, 
Alzheimer’s Disease and Vascular Dementia 
(LipiDiDiet) trial aims to develop a lipid-based 
diet that can delay or prevent the onset of 
dementia. Lipids are a group of molecules such 
as fats, sterols and fat-soluble vitamins, and are 
often consumed in far less than the 
recommended amounts in the human diet. The 
trial is being conducted by researchers at 
Saarland University in Germany, and involves the 
dietary management of nutrient deficiencies, as 
well as providing diet and lifestyle-based health 
care advice for the elderly. For more information, 
visit the LipiDiDiet website at 
http://www.lipididiet.eu. 
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10.2 DRUG TRIALS 
 
Current pharmacological treatment options for 
Alzheimer’s disease (cholinesterase inhibitors 
donepezil, rivastigmine and galantamine and the 
NMDA receptor antagonist memantine) provide 
primarily short-term symptomatic relief, without 
affecting the progression of the disease. There 
are no drugs currently approved in Australia 
specifically for treatment of other forms of 
dementia. There is an urgent need to develop 
and validate disease modifying drugs. 
 
There are enormous challenges for this research 
and despite considerable investment and effort in 
recent years, no such drugs have as yet been 
shown to be effective in phase 3 clinical trials. As 
the pathology associated with Alzheimer’s 
disease begins many years before symptom 
onset, it may be important to identify Alzheimer’s 
disease much earlier in the disease process, and 
find drugs that can modify the progression of the 
disease. There are currently many disease 
modifying drug trials currently underway 
throughout the world. 
 
The primary strategies for stopping or delaying 
the progression of Alzheimer’s disease are based 
on the pathological processes involved in 
development of the disease. They include the 
development of drugs to [147-149]: 
 reduce beta amyloid production 
 prevent beta amyloid aggregation 
 promote beta amyloid clearance 
 inhibit tau phosphorylation or aggregation 
 
Drugs to reduce beta amyloid production are 
designed to block the amount of beta amyloid 
formed in the brain, by inhibiting β-secretase or 
γ-secretase (the enzymes involved in cleaving 
beta amyloid from the amyloid precursor protein). 
Despite promising early results, the few drugs 
tested to date in this category were not effective 
in clinical trials, but research is ongoing [147-
149]. 
Recently, problems with beta amyloid clearance 
rather than an overproduction have been 
suggested to be more important in the 
development of Alzheimer’s disease. 
 
Immunisation strategies are being developed to 
prevent beta amyloid aggregation and plaque 
formation, or to promote beta amyloid clearance 
from the brain. An early active immunisation trial 
was stopped due to adverse effects, but new 
strategies are in development [147-149]. Passive 
immunotherapies based on antibodies against 
beta amyloid are currently in phase 3 clinical 
trials, although, concerningly, one to date has 
produced negative results for people with mild to 
moderate Alzheimer’s disease [150]. 
 
Zinc and copper are involved in beta amyloid 
aggregation and stabilisation of plaques. PBT2 is 
a drug developed and being tested in Melbourne 
that targets copper and zinc to prevent beta 
amyloid aggregation and dissolve plaques 
[147,148]. Animal and early human studies 
suggest PBT2 may improve cognition, but larger 
clinical trials are required. Other inhibitors of beta 
amyloid aggregation are also under investigation 
[149]. 
 
Drugs targeting tau are designed to prevent tau 
from forming neurofibrillary tangles. Lithium has 
shown some promise as an agent that may 
reduce tau phosphorylation and cognitive decline 
but it can have side effects [147]. Other drugs 
targeting tau are currently in phase 3 clinical 
trials. Anti-tau therapies could have widespread 
benefits as tau pathology also occurs in 
dementias other than Alzheimer’s disease [149]. 
 
Other approaches include drugs to limit 
mitochondrial dysfunction (phase 3 trials however 
have not shown benefit), targeted stem cell 
strategies that are still at the proof-of-concept 
stage, and strategies to boost growth of new 
neurons by introducing nerve growth factor into 
the brain that are still in development [148,149]. 
 
Factors that might explain the failure of drug trials 
to date include suboptimal study design 
(inadequate biomarkers and outcome 
measurements) and importantly, the timing of 
treatment in relation to the development of 
disease. Available data from failed phase 3 
studies suggest that people with mild to moderate 
Alzheimer’s disease may be too late in the 
disease process to substantially benefit from 
disease modifying drug treatment [147,149]. 
Recent trials are beginning to address this, 
enrolling participants with prodromal Alzheimer’s 
disease or mild cognitive impairment. Ethical 
issues will need to be addressed for clinical trials 
that involve those with preclinical Alzheimer’s 
disease (defined earlier in this document), as this 
will mean giving unproven drugs to essentially 
healthy people. Researchers announced at the 
Alzheimer’s Association International Conference 
2012 that planning has commenced for three 
such trials [151]. 
 
Even if current phase 3 trials are successful, 
disease modifying treatments are unlikely to 
come onto the market before 2020 [148]. And 
they will not eradicate dementia. The majority of 
dementia cases arise in people aged 80 and 
over, who frequently have mixed Alzheimer’s, 
Lewy body and cerebrovascular pathologies. This 
may limit the effect that therapies targeting 
individual pathologies have on the majority of 
cases of dementia [148]. 
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These drug trials are a promising area of 
research that we hope may result in new 
treatments and interventions for dementia within 
the next ten years. However, to date, none of 
these drugs have been approved for use. 
 
 
10.3 INCREASED RESEARCH FUNDING IS 
NEEDED 
 
Whilst scientific research, particularly over the 
last decade, has shed new hope into the area of 
dementia prevention, much more is needed. 
Additional investment in research to consider the 
prevention, early intervention and treatment of 
dementia, is pivotal in addressing the looming 
epidemic. Dementia research in Australia is 
significantly underfunded compared with other 
chronic diseases that place equally large (or less) 
demand on the health system. 
 
In 2009, the National Health and Medical 
Research Council (NHMRC) spent about $22 
million on dementia research. In comparison, 
cancer attracted nearly $160 million, 
cardiovascular disease around $110 million and 
diabetes over $60 million [152]. A recent analysis 
of NHMRC funding from 2002 to 2011 showed 
that dementia research funding was significantly 
below that for other chronic diseases each year, 
and has not shown the same rate of increase in 
funding over that time as for the other conditions 
[153]. This has meant that since 2002, the 
shortfall in funding for dementia compared to 
diabetes, cancer, cardiovascular disease and 
mental health, has grown significantly. NHMRC 
Fellowships for dementia researchers also 
received far less funding than for other 
conditions, suggesting a major problem of 
research capacity that requires strategies to 
increase the attractiveness of dementia research 
to young scientists [153]. 
 
With dementia being the fourth projected leading 
specific cause of burden of disease and injury in 
Australia in 2010 [154], there is an overwhelming 
need for greater investment in dementia 
prevention and early intervention research. In 
2008, the formal care costs of dementia were 
estimated to be between $3.9 billion and $5.4 
billion, with the cost of replacing family carers 
with paid carers estimated to be $5.5 billion per 
year [155]. Research investment should aim to 
be 1% of the cost of dementia (not including 
informal care costs), or about $50 million per 
annum [155]. This investment is vital to 
continuing Australia’s dementia research effort. 
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11. CONCLUSIONS AND FUTURE 
DIRECTIONS 
 
Australia faces a rapid increase in the number of 
people living with cognitive impairment and 
dementia and in the social and economic costs of 
caring for those people. While there is hope for a 
medical breakthrough and ultimately a cure for 
dementia, we cannot afford to wait for this. 
Without a cure, identifying and addressing risk 
factors in the population remains the most viable 
strategy for preventing cases of cognitive decline 
and dementia and reducing the associated 
financial, societal and individual costs. 
 
The evidence for associations between risk for 
cognitive decline and dementia and several 
modifiable medical and lifestyle factors is well 
established. Proof that modifying these can 
prevent cognitive decline or dementia for either 
individuals or groups does not yet exist, but can 
we afford to wait for this before acting?  More 
research is most certainly needed and is ongoing 
around the world. Promisingly, many experts 
suggest we can do much to reduce dementia 
incidence by implementing preventative health 
strategies now, based on current evidence. 
 
Preventative health is becoming a focus of 
Australian health policy. Maintaining cognitive 
health to date has received little attention with the 
focus very much on physical health. But people 
are concerned about losing cognitive function as 
they age, and public education about potentially 
modifiable risk factors is seen as important. 
Dementia related organisations around the world, 
including Alzheimer’s Australia, are promoting 
risk reduction strategies. 
 
Alzheimer’s Australia will continue to develop and 
evaluate tools and resources which aim to help 
Australians understand the risk and protective 
factors for cognitive decline and dementia, and 
what they can do to reduce their risk. Information 
is provided via printed and online resources, 
community presentations and media campaigns. 
Interactive web-based tools and mobile 
applications are being evaluated for their 
effectiveness in improving knowledge about brain 
health and dementia risk reduction, increasing 
motivation to change unhealthy behaviours to 
address risk factors, and encouraging 
sustainable adoption of strategies to maintain 
brain and heart health. 
 
So what is recommended?  There is good 
evidence to support a range of lifestyle and 
health strategies as a means of reducing your 
risk of cognitive decline or developing dementia. 
 
 Keeping your brain active matters 
o Keep mentally stimulated 
o Engage in social activities 
 
 Being fit and healthy matters 
o Keep physically active 
o Eat healthily, avoiding too much 
saturated fat and including plenty of 
vegetables and fruit 
o Do not be concerned about 
continuing light to moderate drinking, 
but there is no need to start if 
currently a non-drinker 
 
 Looking after your heart matters 
o Regularly check blood pressure, 
blood glucose and cholesterol 
throughout mid and late life and keep 
high blood pressure, diabetes and 
high cholesterol and other vascular 
risk factors well controlled 
o Maintain a healthy body weight 
o Don’t smoke 
 
As a society we are becoming increasingly aware 
of the need to maintain a sound diet, exercise, 
intellectual stimulation and social connectedness. 
This review of the evidence reinforces that 
message and adds a further important impact of 
doing so – maintaining cognitive health and 
reducing dementia risk. It also highlights that 
what is good for the heart is good for the brain. 
We encourage all Australians to look after your 
brain, body and heart because Your Brain 
Matters. 
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GLOSSARY 
 
 
Term Definition 
Adipose tissue Body fat. 
Amyloid plaques Amyloid plaques between nerve cells in the brain is a hallmark 
of Alzheimer’s disease. They are sticky clumps that are formed 
from deposits of beta amyloid protein. 
Antihypertensives Drugs to lower blood pressure. 
Anti-inflammatory agents Drugs to reduce inflammation and pain. 
Antioxidants Antioxidants are naturally occurring substances found in food 
that help to prevent cell damage due to oxidation by free 
radicals. Free radicals are formed during normal metabolism 
and are by-products of the complex chemical processes that 
take place in the cells of our bodies. 
Apolipoprotein E A protein that binds to fat, and transports it around. 
Beta amyloid A protein fragment formed in the breaking down of the amyloid 
precursor protein. In Alzheimer’s disease, these fragments stick 
together to form amyloid plaques. 
Biomarkers Biological indicators of a disease. 
Brain reserve Brain reserve refers to a reserve of healthy brain cells and 
connections between cells and efficient cognitive skills that are 
built up over your lifetime. This reserve can help the brain keep 
functioning well and delay the onset of dementia. 
Brain training Brain training games or programs are structured programs, 
usually computerised, designed to train particular cognitive 
functions by repeated practice. There is no evidence yet that 
brain training can reduce dementia risk. 
Cerebrospinal fluid A liquid that surrounds the brain and spinal cord, protecting 
them from injury. 
Cerebrovascular disease Disease of the blood vessels that damages the blood vessels in 
the brain. 
Cholinesterase inhibitors Drugs to inhibit a brain enzyme and increase levels of a 
chemical (acetylcholine) that is deficient in some dementias. 
Cognitive decline Cognitive decline is a gradual decrease in cognitive abilities over 
time. This is what happens in dementia. 
Cognitive function The cognitive functions of the brain are the higher level thinking 
functions, including memory, learning, attention, language, 
decision making, reasoning, judgement, comprehension, spatial 
skills and planning. 
Crystallised intelligence The ability to use knowledge, experience and skills. 
Dementia with Lewy bodies Dementia with Lewy bodies is a form of dementia characterised 
by the presence of Lewy bodies in the cortex of the brain. Lewy 
bodies damage nerve cells resulting in cognitive problems. 
Enzyme Enzymes are proteins that increase the rates of chemical 
reactions in cells. They help convert molecules into different 
molecules. 
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Term Definition 
Folate Folate, or folic acid, is vitamin B9 and is essential for brain and 
blood cell formation and health. It is found in leafy vegetables 
such as spinach and lettuces, dried or fresh beans and peas, 
sunflower seeds, fruits such as oranges, cantaloupe, honeydew 
melon, banana, raspberry, grapefruit and strawberry, and 
vegetables such as asparagus, beets, broccoli, corn, brussels 
sprouts and bok choy. 
Frontotemporal dementia Frontotemporal dementia is a form of dementia that involves 
damage to the frontal and/or temporal lobes of the brain. 
Behaviour, language and other cognitive skills are affected. 
Hippocampal atrophy A shrinking of the hippocampus, a brain region involved in 
memory and learning. 
Homocysteine Homocysteine is an amino acid in the blood. Amino acids are 
the basic structural units of proteins. At high levels, 
homocysteine can damage blood vessel walls and the blood 
clotting mechanism.   
Hormone Replacement Therapy Use of female hormones in people deficient in these; usually a 
treatment for symptoms of menopause. 
Intervention study A study where an action is taken to try to change outcomes for a 
group of people, e.g. an exercise intervention to improve 
cognitive function in people with Alzheimer’s disease. 
Late-life or old age Late life, or old age, is a normal developmental life stage and 
usually refers to those aged 65 and older. 
Mediterranean diet A diet which places particular emphasis on fruits, vegetables, 
fish and healthy fats. 
Meta-analysis A meta-analysis takes the data from all similar studies and 
combines them, providing an overall result from all the relevant 
research. This is a higher level of evidence that is more 
convincing than a finding from any single study. 
Midlife  Midlife, or middle age, is a normal developmental life stage and 
usually refers to those aged between 40 and 65. 
Mind your Mind The Mind your Mind program was the predecessor to the Your 
Brain Matters program, developed by Alzheimer's Australia. 
Monounsaturated fats Monounsaturated fats, also known as monounsaturated fatty 
acids, can assist with lowering blood cholesterol. 
Monounsaturated fats can be found in olive oil, canola oil, 
macadamia oil, avocado, nuts, and margarines that are labelled 
“monounsaturated”.  
Nerve growth factor A hormone that stimulates growth of some nerve cells. 
Neurocognitive disorder  The fifth version of the Diagnostic and Statistical Manual of 
Mental Disorders, scheduled for release in 2013, will replace the 
term dementia with major neurocognitive disorder, to reflect the 
severity of cognitive impairment at this stage of disease. 
Similarly, the term mild cognitive impairment will be replaced 
with minor neurocognitive disorder. 
Neuroimaging Includes the use of various techniques to provide images of the 
structure or function of the brain. 
Neurofibrillary tangles Neurofibrillary tangles are twisted fibres inside brain cells made 
up of tau protein. They occur in some forms of dementia and 
cause a breakdown in the brain cell's ability to communicate with 
other brain cells. 
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Term Definition 
Observational study Observational studies collect real-life information about 
exposure to a risk or protective factor and subsequent 
development of disease. For example, an observational study 
might measure how much exercise people do, then follow them 
up a number of years later to see who has developed dementia, 
and how that is related to their earlier exercise habits. 
Omega-3 fatty acids Omega-3 fatty acids are a group of unsaturated fats that have a 
role in regulating blood pressure and blood clotting, in helping to 
maintain a healthy immune system, and assisting brain and 
spinal cord function. Omega-3 fatty acids can be found in cold 
water fish (salmon, tuna and sardines), flax (linseeds and cold 
pressed linseed oil), soya beans, walnuts, and dark green 
leaves (spinach and silverbeet).  
Polyunsaturated fats Polyunsaturated fats are an essential part of the diet. Two 
important types are omega-6 fatty acids and omega-3 fatty 
acids. Omega-6 fats are found in vegetable oils such as canola 
and sunflower and are essential for growth, cell structure and 
maintaining a healthy immune system. 
Prodromal Alzheimer's disease The presence of early symptoms indicating the onset of 
Alzheimer's disease. Also called mild cognitive impairment. 
Prospective study A study which follows a group of people forward in time. 
Randomised controlled trial Randomised controlled trials (RCTs) are considered the gold 
standard in determining whether disease risk can be reduced by 
intervening to alter a risk factor. They involve randomising 
individuals to a treatment (e.g. drug or behavioural intervention) 
or a no-treatment (placebo) condition. 
Saturated fats Saturated fats are those that tend to be solid at room 
temperature and can be found in whole milk, cream, butter, 
cheese, meats, coconut oil, palm oil, chicken skin, biscuits and 
pastries. Many ‘fast food’ products, processed meats and deep 
fried food also contain saturated fats. Saturated fats contribute 
to the risk of heart and brain disease by raising blood cholesterol 
levels.  
Secretase enzymes  Proteins that break down larger proteins 
Statins Statins are a class of drugs that lower blood cholesterol levels 
and may be prescribed to people with high cholesterol or with 
heart disease.  
Stroke A stroke is rapid loss of brain function(s) due to disturbance in 
the blood supply to the brain, caused by a blocked or burst 
blood vessel. 
Vascular Vascular means ‘related to blood vessels’. Vascular risk factors 
are those that can affect the health and function of our blood 
vessels, including high blood pressure and high cholesterol. 
Vascular dementia Vascular dementia is a form of dementia associated with 
problems of circulation of blood to the brain. It can sometimes 
result from a stroke or many mini-strokes. 
Vitamin B12 Vitamin B12, or cobalamin, has a key role in the normal 
functioning of the brain and nervous system, and the formation 
of blood. It is involved in DNA synthesis and regulation. It is 
found in fish, meat, poultry, eggs and dairy products. 
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